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Summary 
 
Neurological diseases such as Alzheimer’s disease (AD), Parkinson’s disease 
(PD), Epilepsy and Multiple Sclerosis are included in the Global burden of disease 
study as these disorders have a high impact on public health. Lack of effective 
treatment has motivated the researchers to perform early diagnostics, by 
identifying new gene mutations, which can improve the therapies. The aim of 
this thesis was a genetic analysis of PD using next-generation sequencing data. In 
this thesis, whole genome sequencing (WGS) and whole exome sequencing 
(WES) using DNA from familial PD patients and healthy individuals was 
performed in order to identify the PD causal genes. A large repository of sporadic 
PD WES data and a genotyping array was used to replicate our findings. The PD 
patients from Germany were stratified for clinical trials on the basis of 
mitochondrial endo-phenotype by performing risk profiling of associated Single 
Nucleotide Polymorphisms (SNPs) using exome genotyping array. The sporadic 
PD WES and genotyping array data from International Parkinson’s disease 
Genomics Consortium was used to perform association tests, to determine the 
burden of rare variants in candidate genes of interest. Furthermore, mRNA 
sequencing of all the genes under the PD GWAS loci after knockdown with short 
hairpin RNAs was performed, to identify the actual genes contributing to PD risk 
and the novel pathways involved in PD. Finally, an epistatic interaction of a 
Mendelian PD gene and associated locus was performed to understand the joint 
contribution to PD risk. 
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 Taking everything into account, we identified pathogenic variants in 
known and some novel genes causing PD in families. On the basis of risk profiling 
some of the German PD patients will undergo clinical trials with coenzyme Q10 
and vitamin K2. The association tests using sporadic PD data helped to identify 
some novel genes significantly associated with PD risk. The knockdown 
experiments facilitated the identification of genes contributing to PD risk in 
some of the PD GWAS loci. 
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General Introduction 
 
1.1 Parkinson’s disease 
Parkinson’s disease (PD) was first described as ‘shaking palsy’ by James 
Parkinson in 1817 (Parkinson 2002). It is the second most common 
neurodegenerative disease affecting up to 1% of people above 65 years of age. 
Parkinson’s disease, like other neurodegenerative diseases, is considered to be 
one of the major medical challenges in the society, as there are no treatments 
that can stop the degenerative process. The average age at onset of PD is 
approximately 70 years and is influenced by both genetic and environmental 
factors; hence it can be characterized as a complex polygenic disorder. 
Approximately, 10% of the cases are familial, and the remaining 90% belongs to 
a sporadic form of PD (Papapetropoulos, Adi et al. 2007). 
 The main clinical features of PD are the slowness of movements, muscle 
rigidity and tremor. Mild symptoms such as hyposmia, loss of dexterity, stiffness, 
dragging of a foot, slowness of movements and sleep disturbances are often 
misinterpreted or unnoticed by the patient (Jankovic 2008). In the later stages of 
PD, a speech of the patient is monotonous and slightly slurred, the face is 
expressionless, and the posture is with pill-rolling tremor of the hand (Kalia and 
Lang). 
 Diagnosis of PD requires autopsy which reveals PD's pathognomonic 
hallmark: Lewy bodies (LBs). LBs are abnormal protein aggregates inside the 
nerve cells. There is some heterogeneity depending on the distinct aetiology of 
PD. The postmortem PD brains typically reveal significant neuronal death in the 
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substantia nigra pars compacta (SNpc) with LB inclusions permeating surviving 
neurons (Dickson 2018). In addition to the formation of LBs, alpha-synuclein 
also accumulates in neuronal processes, called Lewy neurites (Lns). These are 
observed either in the brainstem (classical LBs) or in the cerebral cortex (which 
are more frequent in demented PD patients) and are routinely detected by α-
synuclein antibodies (Dickson 2018). Pale bodies precede the formation of LBs 
(Spillantini, Schmidt et al. 1997). Interestingly, α-synuclein seems to follow a 
consistent six-stage spreading pattern starting from the olfactory bulb in early 
stages and resulting in widespread distribution affecting even the cerebral 
cortex in late stages of the disease (Braak, Del Tredici et al. 2003). α-synuclein 
accumulation is not specific to PD as it is observed in a number of other diseases 
including Multiple System Atrophy (MSA), certain forms of neurodegeneration 
with brain iron accumulation (NBIA) and Alzheimer’s disease (AD), and even in 
aged healthy individuals (Dickson, Fujishiro et al. 2008, Lees, Hardy et al. 2009); 
however, accumulation patterns and subcellular distributions differ in each 
disease (Stefanis 2012). Identification of the reasons underlying these variable 
pathological features could contribute to the elucidation of the pathogenetic 
pathways of the disease. 
 
1.2 Epidemiology of PD 
 
Prevalence refers to the proportion of a population with a particular disease at a 
given time point (von Campenhausen, Bornschein et al. 2005). The prevalence of 
PD in Europe ranges between 100 and 300 cases per 100,000 population. 
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Previously published studies on the meta-analysis of prevalence show that it 
rose from 107 cases per 100,000 between ages 50 and 59 years to 1087 cases 
per 100,000 between 70 to 79 years (Pringsheim, Jette et al. 2014). 
 The term incidence refers to the number of new cases in a particular 
population over a period, usually one year (von Campenhausen, Bornschein et al. 
2005). The incidence of PD has been estimated between 10 and 50 cases per 
100,000 population in Europe (Elbaz, Carcaillon et al. 2016). However, the 
number of PD patients is most likely to double by 2030, due to increasing aging 
(Dorsey, Constantinescu et al. 2007). PD is more common in men than in women. 
Prevalence and incidence of PD are lower in Asian population than in European 
and American population (Bolger, Lohse et al. 2014). 
 
1.3 Etiology of PD 
 
In the 1980s, it was observed that a neurotoxin 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) damaged the neurons of the SNpc, resulting in PD 
symptoms (Langston, Ballard et al. 1983). Since that time, several studies have 
reported pesticides as a risk factor of PD (Betarbet, Sherer et al. 2000). Previous 
epidemiological studies examined twins based on cross-sectional information 
and suggested an absence of genetic factors (Wirdefeldt, Gatz et al. 2004). 
However, a few years later, variants were identified in many genes in families 
with an autosomal dominant and recessive mode of inheritance (Lesage and 
Brice 2009). Wirdefeldt et al. applied a longitudinal design and re-evaluated the 
previous cross-sectional data and reported that PD is heritable (Wirdefeldt, Gatz 
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et al. 2011). Hence, the etiology of PD involves both environmental and genetic 
factors. 
1.3.1 Mendelian PD genes:  
 
Although most of the PD cases occur in a sporadic form, in a subset of PD cases 
the disease is inherited in an autosomal dominant or autosomal recessive 
manner. Several genes including SNCA, LRRK2, PARK2, PINK1, DJ1 and VPS35 are 
linked to Mendelian PD and have provided an insight of molecular pathways 
underlying neurodegeneration. 
SNCA: In 1996, Polymeropoulos et al. identified that markers on chromosome 
4q21-q23 were linked to PD phenotype in a large, multigenerational family 
termed “Contursi kindred” (Polymeropoulos, Lavedan et al. 1997) of Italian 
descent with an autosomal dominant mode of inheritance. One year later, the 
same group identified a missense SNCA mutation p. A53T in the same Italian 
family. The mutation p. A53T also segregated in three Greek kindreds with PD 
phenotype. Subsequently, two new SNCA mutations, p. A30P (Kruger, Kuhn et al. 
1998) and p.E46K (Zarranz, Alegre et al. 2004) were reported in other PD 
families. Additionally, a p. H50Q SNCA mutation was reported in two sporadic PD 
cases sharing a common haplotype on the SNCA locus (Appel-Cresswell, Vilarino-
Guell et al. 2013) (Kiely, Asi et al. 2013), and a p. G51D mutation in two familial 
cases (Kiely, Asi et al. 2013, Lesage, Anheim et al. 2013). Interestingly, whole 
gene duplications (Chartier-Harlin, Kachergus et al.) and triplications (Singleton, 
Farrer et al. 2003) also cause PD and severity and age at onset of disease seem to 
correlate with the number of copies of SNCA, indicating a gene-dosage effect 
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(Fuchs, Nilsson et al. 2007). SNCA mutation carriers tend to commonly present 
with dementia and hallucinations, which represents a similar situation to 
dementia with Lewy bodies (DLB) (Houlden and Singleton 2012). Shortly after 
the identification of SNCA mutations as a cause of PD, α-synuclein was identified 
as the major component of Lewy bodies, the pathological hallmark of PD 
(Spillantini, Schmidt et al. 1997) thus linking genetics and apparently sporadic 
forms of the disease (Houlden and Singleton 2012). In neuropathology, there is 
always widespread α-synuclein accumulation with occasional tau deposition in 
patients with SNCA mutations (Poulopoulos, Levy et al. 2012). In a proportion of 
cases, α-synuclein forms oligodendroglial inclusions that are similar to those 
seen in MSA (Markopoulou, Dickson et al. 2008, Obi, Nishioka et al. 2008, Kiely, 
Asi et al. 2013). SNCA plays a significant role in pre-synaptic signaling and 
membrane trafficking (Bendor, Logan et al. 2013). 
 
LRRK2 (PARK8): In 2002, Funayama and colleagues performed two-point 
parametric linkage analysis in a Japanese family, which was already reported in 
1997 with an autosomal dominant parkinsonism. They identified a new locus for 
PD, mapping to chromosome 12p11.2-q13.1 (Funayama, Hasegawa et al. 2002). 
Two years later, Paisán-Ruı́z et al. identified a heterozygous mutation (p. 
R1441G) in LRRK2 in PD patients of 4 families from the Basque region of Spain 
(Paisán-Ruı́z, Jain et al.). Moreover, the same group also identified a 
heterozygous mutation (p. Y1699C) in PD patients from an English family 
(Paisán-Ruı́z, Jain et al.). In the same year, Zimprich and colleagues identified 
heterozygous (p. R1441C) mutations in LRRK2 in a family with an autosomal 
dominant PD (Zimprich, Biskup et al.). Some cases of discordant monozygotic 
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twins carrying the same LRRK2 mutation have been reported in the literature 
(Xiromerisiou, Houlden et al. 2012). The most frequent mutation (p. G2019S) in 
LRRK2 is identified in 20% of Ashkenazi Jewish patients, 40% of Arab ancestry 
and 1-7 % of PD patients of European ancestry (Lesage, Dürr et al. 2006, Ozelius, 
Senthil et al. 2006). Clinical features of LRRK2 mutation carriers appear similar 
to sporadic PD with an onset of 50-60 years but with a predominance of tremor 
and dystonia (Healy, Falchi et al. 2008). In a majority of the cases, LRRK2 
mutations are associated with LB pathology. However, tau, TDP43 and ubiquitin 
positive inclusions are also occasionally reported (Rajput, Dickson et al. 2006). 
 LRRK2 also known as dardarin consists of 51 exons and encodes leucine-
rich repeat kinase 2, a large protein consisting of an ankyrin repeat region, a 
leucine-rich repeat (LRR) domain, a kinase domain, a DFG-like motif, a RAS 
domain, a GTPase domain, a MLK-like domain and a WD40 domain (Bolger, 
Lohse et al. 2014). Dardarin has an enzyme function known as kinase activity 
and is involved in the process of phosphorylation. LRRK2 regulates autophagy 
through a calcium-dependent activation of the CaMKK/AMPK signaling pathway 
and also plays a role in synaptic vesicle trafficking (Bolger, Lohse et al. 2014). 
 
 PRKN (PARK2): In 1998, Kitada et al. identified a homozygous deletion in 
PARK2 in a nuclear consanguineous Japanese family with an autosomal recessive 
juvenile parkinsonism (Kitada, Asakawa et al. 1998). PARK2 mutations were 
identified by linkage analysis and consist of homozygous, compound 
heterozygous and heterozygous mutations, as well as exonic deletions and 
duplications. Most of these mutations have been identified in familial cases and 
some have also been identified in sporadic PD cases (Clark, Afridi et al. 2006). In 
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2007, Kay and colleagues reported that heterozygous mutations in PARK2 do not 
contribute to PD (Kay, Moran et al. 2007). An early onset PD patient carries 
PARK2 mutations often before 45 years of age. PARK2 mutation carriers manifest 
a consistent response to levodopa treatment, and motor dysfunction 
progressively declines in patients at a young age. Clinical features of PARK2-
linked PD are focal dystonia, psychosis, early instability or atypical L-dopa 
induced dyskinesia (Chan, Mok et al. 2008). Pathological alterations are usually 
restricted to the SNpc and LBs are uncommon (Poulopoulos, Levy et al. 2012, 
Doherty, Silveira-Moriyama et al. 2013). 
 PARK2 spans 1.38 Mb and encodes the protein, Parkin. It functions as an 
E3 ubiquitin ligase, which plays a major role in ubiquitin proteasome system 
(UPS) by tagging abnormal proteins for degradation (Chan and Chan 2011). 
PARK2 also plays a significant role in autophagy of impaired mitochondria 
(Fiesel, Caulfield et al. 2015). 
  
PINK1 (PARK6): Homozygosity screening in a PARK2 negative large Marsala 
kindred from Sicily, identified the gene PTEN induced putative kinase 1 (PINK1) 
(Valente, Bentivoglio et al. 2001). Three years later, the same group identified 
two homozygous mutations (p. G309D and p. W437X) in a consanguineous 
Spanish family and two Italian families, respectively (Valente, Abou-Sleiman et 
al. 2004). PINK1 is the second most frequent cause of early-onset PD (Hatano, Li 
et al. 2004, Valente, Abou-Sleiman et al. 2004, Piccoli, Ripoli et al. 2008). 
Moreover, the heterozygous mutations are speculated to be involved in the 
development of PD (Klein, Djarmati et al. 2005, Choi, Woo et al. 2008). 
Neuropathological features of PINK1 mutation carriers are similar to those of 
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patients with PARK2 mutations, and also the age at onset of the patients is less 
than 50 (Poulopoulos, Levy et al. 2012). 
 PINK1 encodes serine/threonine protein kinase and is localized in the 
mitochondria. It plays a major role in protecting cells from stress-induced 
mitochondrial dysfunction (Matsuda, Kitagishi et al. 2013). 
 
DJ1 (PARK7): In 2003, Bonifati and colleagues performed homozygosity 
mapping and positional cloning in two consanguineous families from a 
genetically isolated population in the Netherlands and identified a homozygous 
deletion of exons 1 to 5 in DJ1 (Bonifati, Rizzu et al. 2003). Moreover, a missense 
mutation (p. L166P) in DJ1 was identified in an Italian family with an autosomal 
recessive PD (Bonifati, Rizzu et al. 2003). Mutations in DJ1 are a rare cause of 
autosomal recessive PD (Abou-Sleiman, Healy et al. 2003, Bonifati, Rizzu et al. 
2003, Hering, Strauss et al. 2004). Age at onset of PD patients is less than 30 
years. They are responsive to levodopa and show atypical features such as 
dysarthria and myoclonic jerks. DJ1 mutations are roughly characterized by 
0.8% of familial and 0.4% of sporadic PD cases (Kilarski Laura, Pearson Justin et 
al. 2012). The neuropathology related to DJ1 mutations has not been studied to 
date. 
 
VPS35: In 2011, Vilariño-Güell et al. performed exome sequencing in a 
multigenerational Swiss family with an autosomal dominant mode of inheritance 
and identified a heterozygous mutation p. D620N in VPS35. However, the VPS35 
p. D620N variant exists not only in familial PD cases but also in sporadic PD 
cases (Vilariño-Güell, Wider et al.). The clinical presentation of VPS35 mutation 
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carriers resembles individuals with classic late-onset, levodopa-responsive PD. 
VPS35 encodes a subunit of the retromer cargo recognition complex and serves 
as a key player in endosomal-lysosomal trafficking (Mukadam and Seaman 
2015). 
 
1.3.2 Other genetic risk factors 
 
GBA: Homozygous mutations in GBA causes a lysosomal storage disorder known 
as Gaucher’s disease (Tsuji, Choudary et al. 1987, Koprivica, Stone et al. 2000). 
Major risk factors in PD are heterozygous GBA mutations (O'Regan, deSouza et al. 
2017). Approximately 300 variants including insertions, deletions, frameshift 
and splice site mutations have been reported in this gene (Hruska, LaMarca et al. 
2008). However, the two most common mutations in GBA are p. N370S and p. 
L444P (Tan, Tong et al. 2007, Gutti, Fung et al. 2008, Mata, Samii et al. 2008, 
Neumann, Bras et al. 2009). The frequency and prevalence of the mutations in 
GBA vary among different ethnicities (Mitsui, Mizuta et al. 2009). Age at onset for 
a patient with GBA mutation is before 50 years and is likely to develop dementia 
than sporadic PD patients. They show a good response to Levodopa. Recently, 
GBA mutations also increase the risk for DLB, thus showing a link between 
lysosomal biology and -synuclein (Goker-Alpan, Giasson et al. 2006). 
 Published reports suggest that the loss of Glucocerebrosidase enzyme 
activity impairs the lysosomal function and results in endoplasmic reticulum 
stress, which contributes to the PD pathogenesis (Fernandes, Hartfield et al. 
2016).  
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MAPT: Non-synonymous mutations in MAPT cause fronto-temporal dementia 
with Parkinsonism (FTDP-17), which includes Pick’s disease (Hutton, Lendon et 
al. 1998). The MAPT locus on chromosome 17 includes approximately 900 
kilobase inversion that leads to 1.3 megabase linkage disequilibrium region 
named as H1 and H2 haplotypes (Allen, Kachadoorian et al. 2014). The most 
common MAPT H1 haplotype has been linked not only to Alzheimer’s disease 
(AD), progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) 
but also to PD (Pascale, Di Battista et al. 2016). Moreover, GWAS has confirmed 
H1 haplotype as a risk factor for PD (Kay, Moran et al. 2007). Neuropathology of 
PD demonstrates the presence of tau, localized within glial and neuronal 
inclusions (Cookson, Hardy et al. 2008). Although the absence of LB does not 
exclude PD in the differential diagnosis, it suggests pathogenic MAPT mutations 
are not responsible for typical PD and that it is likely that the pathological 
mechanism underlying FTPD-17 is distinct from that in typical PD (Coakeley and 
Strafella 2017). MAPT encodes the microtubule-associated protein tau, whose 
transcript undergoes complex alternative splicing and generates six different 
isoforms. It plays a major role in microtubule assembly and stability, axonal 
transport, cellular signaling and protein fibrilization (Zhang, Xing et al. 2016). 
 
1.4  Genome wide association study (GWAS) 
Risch and Merikangas formulated GWAS in 1996 (Risch and Merikangas 1996). 
In a GWAS study, statistical comparison of allele frequencies between cases and 
controls is performed, and it should include more than 1000 cases and controls 
and >300,000 markers (Balding 2006). All GWAS completed till date are 
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published in the GWAS catalogue (https://www.ebi.ac.uk/gwas/). GWAS has the 
power to study the genetic basis of disease by assaying the entire genome. 
However, several criticisms have been put forward for the usage of GWAS. 
Firstly, some of the risk loci identified through GWAS has small effect size and 
are not clinically useful as they fail to explain disease risk; nevertheless, these 
loci have shed light on the biological pathways involved in disease pathogenesis. 
Moreover, risk variants with odds ratio less than 1.5 could be false positives due 
to population stratification. Finally, the risk variants identified through GWAS 
are usually present in the non-coding region, which does not have a clear 
function, though they could act as proxies for the causative variant (Visscher, 
Wray et al. 2017). 
GWAS in PD:  
The first PD GWAS was performed in 2006 with an underpowered study of 537 
cases and controls that failed to identify any risk loci (Maraganore, de Andrade et 
al. 2005, Fung, Scholz et al. 2006). In 2009, two independent GWAS were 
performed in the Caucasian and Asian population with a larger sample size 
(Satake, Nakabayashi et al. 2009, Simon-Sanchez, Schulte et al. 2009). LRRK2, 
SNCA and PARK16 were significantly associated with PD in both studies. BST1 
and MAPT were linked to PD in the Asian and Caucasian study, respectively. In 
two independent studies, two new risk loci, GAK/DGKQ and HLA region were 
identified and the role of SNCA and MAPT in PD susceptibility were supported 
(Pankratz, Wilk et al. 2009, Hamza, Zabetian et al. 2010). Furthermore, a large-
scale meta-analysis of 13,708 cases and 95,282 controls shows that 24 risk loci 
are significantly associated with PD risk (Nalls, Bras et al. 2015). The SNCA and 
LRRK2 locus has been continuously detected in GWAS, confirming they are 
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related to both familial and sporadic PD. In 2016, Lesage and colleagues reported 
that a rare deleterious variant in VPS13C is a cause of autosomal recessive early-
onset parkinsonism (Lesage, Drouet et al. 2016). This locus has also been 
associated with sporadic PD as per largest meta-analysis of 2014 (Nalls, 
Pankratz et al. 2014). The PARK16 locus contains five protein-coding genes 
(SLC45A3, NUCKS1, RAB29, SLC41A1 and PM20D1). Several lines of evidence 
show that a molecular interaction between RAB29 and LRRK2 may be associated 
with PD (MacLeod, Rhinn et al. 2013). The GAK/DGKQ locus contains protein-
coding genes including GAK, TMEM175 and DGKQ. GAK contributes to modify -
synuclein expression and toxicity in PD (Dumitriu, Pacheco et al. 2011). 
Moreover, it also plays a major role in regulating clathrin-mediated membrane 
trafficking (Zhang Claire, Engqvist-Goldstein Åsa et al. 2005). 
 Recently, Chang et al. carried out a GWAS of 6,476 PD cases and 302,042 
controls of European ancestry and identified 17 new PD risk loci in a joint 
analysis of 26,035 PD cases and 403,190 controls (Chang, Nalls et al. 2017) 
(figure 1).  
 
 
Figure 1: Manhattan plot from a GWAS meta-analysis for Parkinson’s disease. Reproduced 
from Chang et al. 2017. 
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1.5 Pathways in Parkinson’s disease  
 
In both sporadic and hereditary form of PD, there is a loss of dopamine neurons 
in the SNpc. Moreover, impairment of endoplasmic reticulum (ER) function, 
protein degradation pathways, intracellular trafficking and calcium signaling 
enhances the degeneration of dopamine neurons (Michel, Hirsch et al. 2016). 
Down-regulation of autophagy leads to inclusion bodies, i.e. accumulation of 
aberrant proteins, contributing to the pathogenesis of neurodegenerative 
diseases. Two SNCA mutations p. A30P and p. A53P have been involved in the 
deterioration of Chaperone mediated pathway (Sala, Marinig et al. 2016). LRRK2 
plays a role in signaling pathways such as vesicle trafficking, mitochondrial 
function as well as endocytosis and autophagy. Two frequent LRRK2 mutations p. 
G2019S and p. R1441C increases mitochondrial autophagy and accumulation of 
autophagic vacuoles, resulting in degeneration of dopaminergic neurons 
(Esteves and Cardoso 2016). 
 Endoplasmic reticulum (ER) plays a role in cellular homeostasis by 
maintaining proper protein folding and quality control. Aggregation of -
synuclein disrupts ER-Golgi vesicular trafficking and leads to ER stress. 
Furthermore, when Parkin is downregulated, it increases ER stress induced 
mitochondrial dysfunctions (Jiang, Gan et al. 2010). Hence, in order to prevent 
neurodegeneration and preserve normal physiology, it is crucial to prevent ER-
mitochondria impairment, so that the calcium transfer between the two 
compartments is not reduced. 
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 The major sources of oxidative stress such as mitochondrial dysfunction, 
impairment of protein degradation pathway and neuroinflammation are 
discussed below. 
 
1.5.1 Mitochondrial dysfunction 
 
MPTP is oxidized to MPP+ and inhibits the activity of complex I of the 
mitochondrial electron transport chain in the drug abusers (Langston, Ballard et 
al. 1983). Complex I inhibition increases the ROS production. In 1990, Schapira 
et al. have reported complex I deficiency in the SNpc of patients with sporadic PD 
(Schapira, Cooper et al. 1990).  
 Mutations in PINK1 and PARK2 are identified in patients with an 
autosomal recessive PD (Kitada, Asakawa et al. 1998) (Valente, Abou-Sleiman et 
al. 2004). Both these genes play a major role in mitophagy, i.e. degradation of 
impaired mitochondria. PARK2 deficiency leads to oxidative stress, which in turn, 
impairs mitochondrial function (Muftuoglu, Elibol et al. 2004). Animal model’s 
studies show that deficiency of PINK1 leads to loss of dopamine neurons in SNpc, 
abnormal mitochondrial morphology, inhibition of complex I activity, and 
increase in oxidative stress (Clark, Dodson et al. 2006, Gautier, Kitada et al. 
2008). DJ1 binds to the mitochondrial complex I subunit and regulates its activity 
(Hayashi, Ishimori et al. 2009). It has been shown to be more protective against 
oxidative stress-induced cell death. A published study has reported a loss of 
nigrostriatal dopamine neuron in DJ1 knockout mouse (Goldberg, Pisani et al. 
2005). Moreover, this DJ1 knockout mouse showed altered mitochondrial 
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morphology and respiration as well as reduced membrane potential and 
accumulation of impaired mitochondria (Goldberg, Pisani et al. 2005, Krebiehl, 
Ruckerbauer et al. 2010). 
 
1.5.2 Impairment of protein degradation pathway 
 
Protein misfolding and aggregation are common mechanisms in most of the 
neurodegenerative diseases including PD. A pathological hallmark of PD is an 
aggregation of -synuclein. Ubiquitin Proteasome system (UPS) plays a major 
role in the removal of abnormal proteins. Mutations in PD-related genes 
increases oxidative stress, which impairs the function of UPS that degrades 
damaged and misfolded proteins (Blesa, Trigo-Damas et al. 2015). The first 
genetic link for involvement of UPS in neurodegeneration was provided by the 
discovery of variants in PARK2 in a family with an autosomal recessive juvenile 
parkinsonism (Kitada, Asakawa et al. 1998). This gene encodes E3 ubiquitin 
ligase, which plays a significant role in UPS by modulating 26S proteasome 
activity (Chan and Chan 2011). Furthermore, mutations in UCHL1 in a family 
with PD has provided additional support for the role of UPS in 
neurodegeneration (Leroy, Boyer et al. 1998). This gene encodes Ubiquitin C-
Terminal Hydrolase L1 and is involved in the processing of ubiquitinated 
proteins. 
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1.5.3 Neuroinflammation 
 
Neuroinflammatory mechanism, which is primarily controlled by activated 
microglia, contributes to the dopaminergic cell death in PD. Activated microglia 
have been found in the olfactory bulb and in the SNpc of both familial and 
sporadic PD patients (Le, Wu et al. 2016). Environmental toxins can shift 
microglia to an over-activated state and release ROS which can cause 
neurotoxicity (Blesa, Trigo-Damas et al. 2015). -synuclein released from the 
neuronal cells activates the microglial inflammatory response. Mutations in 
LRRK2 contributes to neurotoxicity by increasing the proinflammatory cytokine 
release from activated microglial cells (Gillardon, Schmid et al. 2012). Loss of 
function mutations in PARK2 leads to inflammation-related degeneration of 
dopamine neurons (Frank-Cannon, Tran et al. 2008). DJ1 negatively regulates 
inflammatory response of microglia and astrocytes by making easy the 
interaction between STAT1 and SHP1 (Kim, Choi et al. 2013).  
 
Figure 2: Pathways in Parkinson’s disease. Reproduced from Blesa et al. 2015. 
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1.6 Next generation sequencing:  
 
DNA sequencing was first established by Sanger in 1970s (Sanger and Coulson 
1975). However, the technique was expensive and too laborious for the 
sequencing of the whole genome. Over the past decade, second generation 
sequencing has been developed and have reduced the time and cost required for 
sequencing. Moreover, Whole Exome Sequencing (WES) and Whole Genome 
Sequencing (WGS) have enhanced identification of genetic defects in rare 
diseases (Saunders, Miller et al. 2012, Turro and BioResource 2016). 
Furthermore, genetically heterogeneous diseases can be diagnosed by 
simultaneously sequencing panel of genes associated with the disorder. 
 
Whole Exome/Genome sequencing analysis: 
 
The most important question for familial analysis is to use either WGS or WES. 
WGS is the most relevant option as it allows interrogating SNVs, indels, 
structural variants and copy number variants in both coding as well as a non-
coding region of the genome (Gilissen, Hehir-Kwa et al. 2014). In the case of 
WES, reads are targeted to only protein-coding regions, so they represent less 
than 2% of the genome. WES can be useful in large population studies as its cost 
is less than WGS and it allows increasing the sample number. Moreover, the high 
coverage in WES helps to detect variants more accurately (Biesecker, Shianna et 
al. 2011). After sequencing, all the short sequence reads are mapped to the 
human reference genome. The accuracy of variant detection depends on the 
depth of coverage and DNA quality. Several tools have been developed to detect 
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SNVs, small INDELs as well as copy number variants like large deletions, 
insertions or structural variants such as inversions and chromosomal 
rearrangements. The identified variants can be annotated using several tools 
such as KGGSEQ (Cingolani, Platts et al. 2012), ANNOVAR (Wang, Li et al. 2010), 
and SNPEFF (Cingolani, Platts et al. 2012). Around 3 to 4 million SNVs and 
structural changes (deletions, insertions, inversions) exist in a genome of an 
individual. Moreover, approximately 20,000 variants are present in the coding 
regions, and an estimated 10,000 variants are non-synonymous, i.e. they change 
the protein sequence (Biesecker, Shianna et al. 2011). Hence, it is quite 
challenging to identify the variants relevant to the trait. However, 90% of the 
detected non-synonymous variants are common, i.e. their frequency is >1% in 
the population. These common variants are filtered out, as they are not often 
disease causal in rare Mendelian disorders. These rare genetic variants are 
functionally annotated by predicting their probable consequences at the protein 
level. Several prediction tools such as SIFT (Kumar, Henikoff et al. 2009), 
Polyphen (Chun and Fay 2009), GERP (Davydov, Goode et al. 2010), SNAP, CADD 
(Kircher, Witten et al. 2014), PhyloP (Pollard, Hubisz et al. 2010), and 
MutationTaster have been developed to distinguish deleterious variants from 
neutral ones and hence to determine the impact of non-synonymous SNVs on 
protein function. This in-silico prediction is based on previous knowledge from 
databases and it includes analysis such as conservation among species, splicing 
predictions and biochemical properties of the amino acids. Moreover, a genetic 
variant has a causal role in a patient only if it is present in all affected members 
and/or is carried by unaffected family members. Hence, family co-segregation 
using Sanger sequencing is often required, confirming variants of interest. 
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Figure 3: Whole genome/exome sequencing data analysis. Reproduced from Foo et al, 
2012. 
 
1.7 Aims of the thesis: 
 
Advanced genomic technologies have illuminated the genetic underpinnings of 
devastating neurological disorders such as Parkinson’s disease (PD), Alzheimer’s 
disease (AD) and Amyotrophic Lateral Sclerosis (ALS). Such discoveries have 
been facilitated by genome-wide association studies (GWAS) and next-
generation sequencing (NGS) investigations, which allow the identification of 
common and rare variants contributing to disease risk. 
 
 34 
  Project 1: The aim was to identify the causal gene by investigating 
WGS/WES data from familial PD samples (discovery cohort). Further, to screen 
the candidate genes from discovery cohort in a large repository of WES sporadic 
PD data from Parkinson’s disease Genetics Sequencing Consortium (PDGSC). 
Moreover, to perform genetic replication by investigating the burden of rare 
variants in sporadic PD cases compared to controls using WES data and a 
genotyping array NeuroX. Finally, to perform weighted gene co-expression 
network analysis using publicly available RNA-sequencing data generated using 
prefrontal cortex tissues from postmortem PD patients. 
 Project 2: Several published studies have reported that impairment of 
mitochondrial function increases oxidative stress and promotes aging and 
neurodegeneration. Mitochondrial dysfunction plays a major role in PD 
pathogenesis. The goal of this project was to stratify PD patients for medical 
trials on the basis of mito-endophenotype. Additionally, to determine the burden 
of rare variants in mitochondrial-related genes in sporadic PD cases compared to 
controls. 
 Project 3: GWAS in PD has identified many loci implicated in disease risk. 
However, most of the genes responsible for this risk are still unknown. This 
project aimed to identify the gene(s) from each risk loci, which is responsible for 
the identified risk. In order to achieve this goal, genes under the GWAS loci were 
knockdown by shRNA and followed by mRNA sequencing to understand the 
behaviour of Mendelian PD genes. Further, to identify gene ontologies and 
pathways over-represented in differentially expressed genes. 
 Project 4: GWAS has provided evidence that PARK16 locus and LRRK2 are 
associated with PD. Previous published molecular biology studies have shown an 
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interaction between PARK16 locus and LRRK2. In this study, the aim was to 
determine the genetic interaction between genes under the PARK16 locus and 
LRRK2 by interrogating a large repository of WES data. 
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Project 1: Identification of risk variants in 
Parkinson's disease using whole exome and 
whole genome sequencing. 
 
1.1 Introduction 
In the past two decades, Next Generation Sequencing (NGS) has been extensively 
used in genomic studies. As the cost of NGS has decreased, family-based 
sequencing analysis has been increasingly used to identify causal genes for 
Mendelian disorders. Family-based analysis has an advantage to utilize co-
segregation of variants with the disease within families, which helps to 
distinguish causal from non-causal ones and also the joint variant calling across 
all family members increases the accuracy of variant calling. These advantages 
and continuing decrease in the cost of NGS technology, exome/genome 
sequencing have been widely used for research of Mendelian disorders 
(Stavropoulos, Merico et al. 2016). 
  Previously, several genes with Parkinson’s disease (PD) causal mutations 
have been identified in families with Mendelian inheritance and suggest that 
increased oxidative stress, mitochondrial and lysosomal dysfunction and 
abnormal handling of misfolded proteins by ubiquitin-proteasome and 
autophagy-lysosomal systems, contribute to PD (Blesa, Trigo-Damas et al. 2015). 
In order to understand the genetic architecture of PD in the general population, 
it is essential to elucidate the strong effects of rare alleles on disease risk in 
families. However, causal variants have been facilitated using filtering strategies 
based on segregation, annotation and quality control. 
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 We performed a two-stage study to face challenges that are ingrained in 
gene discovery in complex disorders. Firstly, we investigated exomes/genomes 
from 126 families with PD. Furthermore; exonic variants with minor allele 
frequency (MAF) less than 1% in all public databases and segregated in the 
family members were prioritized as interesting candidates. In the second stage, 
the most promising genes from the families were investigated in a replication 
cohort comprising the large repository of whole exome sequencing (WES) data 
of 2,859 sporadic PD patients and 690 controls from the Parkinson’s disease 
Genetics Sequencing Consortium (PDGSC) as well as 1,732 controls from the 
Rotterdam study (RSX1) WES data. Furthermore, gene-based association tests 
were performed using sporadic PD WES data and NeuroX genotyping data  
(Nalls, Bras et al. 2015) to estimate the burden of rare variants in the sporadic 
PD cohort against controls. Finally, publicly available RNA-sequencing data from 
postmortem human brain samples of 29 PD cases and 41 controls were utilized 
to generate weighted gene co-expression network (Dumitriu, Golji et al. 2016).  
 
1.2 Subjects and Methods: 
1.2.1 Discovery phase 
Subjects: A total of 180 DNA samples from the Netherlands, Turkey, Spain, 
Tunisia, Italy, Portugal and Germany were collected from 117 families with an 
autosomal dominant (AD) or autosomal recessive (AR) PD. Additionally, 20 DNA 
samples from 9 Turkish families with an AD and AR mode of inheritance were 
provided by Dr. Ebba Lohmann. For a detailed list of samples included in this 
study as well as the clinical characteristics for each cohort, see table 1. A total of 
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0.5-1ug of DNA from the 180 individuals was shipped to Macrogen 
(http://www.macrogen.com/) for Whole Genome Sequencing (WGS), and DNA 
from the additional 20 individuals from Turkey was sent to CeGAT 
(https://www.cegat.de/) for WES. 
Sample preparation: Samples were prepared according to the Illumina TruSeq 
Nano DNA library preparation guide or TruSeq DNA PCR-free library 
preparation guide depending on quality and the total amount available. Libraries 
were sequenced using Illumina HiSeqX sequencer (www.illumina.com). 151 
paired-end reads were produced. 
Table 1: Sample details and clinical characteristics of WGS/WES. 
Cohort Number of 
families 
Number of 
cases 
Number of 
controls 
AAO (mean  
SD) 
Cases 
(Males) 
Cases 
(Females) 
Italy 23 28 2 56.03  11.71 15 13 
Nijmegen 10 10 0 47  13.09 5 5 
Spain 8 15 4 65.6  10.96 5 10 
Tübingen 10 10 0 54.8  7.7 4 6 
Tunisia 3 6 3 57.5  15.35 4 2 
Turkey 22 29 17 41.37  16.09 17 15 
Portugal 11 13 1 54.75  14.85 7 6 
SCOPA 3 3 0 51.79  16.48 NA NA 
GRIP_NL 36 39 19 - 18 21 
*AAO: Age at onset 
 
 
1.2.1.1 SNPs and INDELs 
 
Sequence reads were aligned to the human reference genome (hg19) using 
Burrows wheeler algorithm (BWA) (Chang, Nguyen et al. 2010). Sorting, 
indexing and PCR duplicate marking were performed using Picard tools 
(http://broadinstitute.github.io/picard). Variant calling and indel recalibration 
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was performed with GATK practices (McKenna, Hanna et al. 2010). A VCF file 
(Variant Call format) with variants identified by WGS was then generated for a 
total of 180 individuals as well as for variants identified by WES for 20 
individuals from the respective 126 families. The VCF files comprising 
individuals from the same family were utilized for further analysis.  
 Quality control (QC) was performed using VCFtools (Danecek, Auton et al. 
2011) and KGGSeq (Cingolani, Platts et al. 2012). In brief, genotypes with a 
Phred quality score below 20, a read depth of less than 10, the second smallest 
normalized Phred-scaled genotype likelihood below 20, those with the fraction 
of reads carrying alternative allele >= 5% at a reference-allele homozygous 
genotype, the fraction of reads carrying alternative allele <= 25% at a 
heterozygous genotype, or the fraction of the reads carrying alternative allele <= 
50% at an alternative-allele homozygous genotype were set to missing (./.). 
Variants with the ‘FILTER’ field not matching the label ‘PASS’, a minimum overall 
sequencing Phred quality score below 50, an overall mapping quality Phred 
score below 20, an overall strand bias Phred-scaled p-value (using Fisher's exact 
test) above 6, and those within putative super-duplicate genomic regions as 
defined in genomic SuperDupsdataset 
(http://hgdownload.cse.ucsc.edu/goldenPath/hg18/database/) were removed 
from further analysis. We also filtered out variants with a disease allele 
frequency above 0.01 in 1000 Genomes (www.1000genomes.org), dbSNP138, 
dbSNP141, gnomAD browser (http://gnomad.broadinstitute.org/) the Exome 
Variant Server (http://evs.gs.washington.edu/EVS/) or ExAC 
(http://exac.broadinstitute.org/); or our in-house whole-genome/exome 
database from more than 3,000 neurologically healthy individuals. Variants in 
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families in which an autosomal dominant mode of inheritance was suspected 
were further filtered for a disease allele frequency of 0.001.  
 In a last step of QC, variants with genotypes not consistent with the 
disease inheritance pattern (autosomal dominant or autosomal recessive) 
assumed for each family were removed from further analysis. BEAGLE 4.0 
(http://faculty.washington.edu/browning/beagle/beagle.html) was used to 
estimate the phase in each family and, consequently, detect compound 
heterozygous variants. 
 Gene-based and deleteriousness prediction annotations were applied to 
each variant surpassing the QC filters mentioned above using UCSC RefGene 
(https://genome.ucsc.edu), GENCODE (https://www.gencodegenes.org), UCSC 
KnownGene (hg19) and dbNSFP database 
(https://sites.google.com/site/jpopgen/dbNSFP). These variants were also 
annotated for protein-protein interactions according to STRING (http://string-
db.org/) and BioGRID (http://thebiogrid.org/) databases.  
 Segregating variants were also scored for their presence in Identity by 
Descent (IBD; autosomal dominant families) or Homozygous by Descent (HBD; 
recessive families) segments. These segments were detected using BEAGLE 4.0 
and were only possible in some of the families included in this project. For the 
rest of families, Identity by State segments (IBS; dominant families) and Runs of 
Homozygosity (ROH; recessive families) were detected using PLINK 1.90 beta 
(Purcell, Neale et al. 2007). A final step of annotation included cross-reference 
with the PDGene database (http://pdgene.org/) as well as brain expression 
databases such as GTEx Portal (http://www.gtexportal.org) or BioGPS 
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(http://biogps.org/). 
1.2.1.2 Structural variants/Copy number variants 
Structural variants (SV) are large chromosomal rearrangements usually larger 
than 1kb that includes Copy Number Variation (CNV), inversions and 
interchromosomal translocations. CNV includes deletions and duplications with 
the region of DNA >1kb (Escaramís, Docampo et al. 2015).  
 SVs were called using Manta (Chen, Schulz-Trieglaff et al. 2016) from 
mapped paired-end sequencing reads. Manta identifies candidate SVs from the 
discordant pair and split-read alignments, then performs local assembly and 
realignment to refine candidates (Chen, Schulz-Trieglaff et al. 2016). The BAM 
files derived from the step mentioned in the previous section were used as input 
of Manta, and all the SVs were reported in VCF format. Manta has some 
limitations such as unable to detect dispersed duplications and fully-assembled 
large insertions. 
 CNV for all the genome sequenced samples were called using 
computationally efficient software ERDS (estimation by read depth with single-
nucleotide variants) (Zhu, Need A  et al. 2012). This tool combines paired-end 
information, read depth and polymorphism using Hidden Markov Model to 
predict CNVs. The BAM and VCF files were used as input of ERDS. The output 
includes copy numbers and scores calculated using the Poisson model (Zhu, 
Need A  et al. 2012). Higher the score, more reliable is the CNV. The length of 
CNV is also an essential factor. Poisson scores are missing for small deletions 
(1kb). 
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 Genomic regions including centromeres, telomeres, immunoglobulin, gap 
locations, repeat masked regions, GC percent greater than 90 and less than 10, 
common CNVs from Database of Genomic Variants (DGV) 
(dgv.tcag.ca/dgv/app/home) and low mappable regions overlapping with the 
CNVs and SVs were removed. All the small length CNVs with missing Poisson 
scores were removed. CNVs and SVs segregating in the families were retained 
and confirmed after visualization in Integrative Genomics Viewer (IGV) 
(Robinson, Thorvaldsdóttir et al. 2011). 
 
1.2.2 Replication phase 
 
1.2.2.1 Gene identification in sporadic WES dataset 
 
The candidate genes identified in discovery cohort were screened in WES data 
comprising 2,859 sporadic PD cases and 690 controls from Parkinson’s disease 
Genetics Sequencing Consortium (PDGSC) as well as 1,732 controls from the 
Rotterdam study (RSX1) WES data. This screening allowed not only to reduce the 
number of false positives but also to investigate the role of candidate genes in 
the general population.  
 The 100-bp paired-end reads from PDGSC were aligned to the human 
reference genome (hg19) using BWA-MEM (Chang, Nguyen et al. 2010). Variants 
were called and recalibrated using GATK (McKenna, Hanna et al. 2010). High-
quality variants were selected by applying standard GATK filter steps with 
minimum genotype Phred score of 20, depth of 8 and all the variants with the 
‘FILTER’ field matching the label ‘PASS’. Colleagues from the PDGSC performed 
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quality control of this dataset. All the samples without 15X minimum coverage 
and not in 85% coverage of the broad canonical exome intervals were excluded. 
All the subjects with an excessive number of singletons (>500) were removed. 
Individuals with the ratio of transition to transversion (Ti/Tv) >3 SD from the 
mean and mean depth per alternative allele less than 25 were excluded. All the 
variants with minimal coverage of 15X per variant in cases or controls as well as 
a study-specific differential depth threshold (anywhere from P <1E-50 to P <1E-
150) were removed. Moreover, variants were removed on the basis of maximal 
missingness of 15% per variant in cases or controls as well as a study-specific 
differential missingness threshold (anywhere from P <1E-6 to P <1E-25) based 
on distributions. Individual quality control was also performed which includes 
removal of divergent ancestry samples, duplicates, heterozygosity and missing 
genotype outliers and samples with discordant sex information. After quality 
control, we were left with 1,472,032 variants. We prioritized the rare 
(MAF<0.01) coding variants from the sporadic WES data and screened our 
candidate genes, which were identified using the discovery cohort.  
1.2.2.2 Association analysis: 
 
Gene-based optimal sequence kernel association test (SKAT-O) was performed 
using rare variants (MAF<0.01). SKAT-O is a combined test which selects 
significant result by comparing the one-sided model of burden test (all variants 
have the same direction of effect) and two-sided model of SKAT test (all variants 
have a distinct direction of effect) (Lee, Emond et al. 2012). It computes gene-
based p-values by correcting population stratification with the inclusion of 20 
multi-dimensional scaling components as covariates. 
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 The following four criteria were used to see the enrichment of rare 
variants: 
• all the rare variants. 
• Functional variants (frameshift, non-frameshift, start-loss, stop-loss, stop-
gain, splicing, missense, exonic, 5-prime untranslated region (UTR5), 3-
prime untranslated region (UTR3), upstream (-100bp), downstream 
(+100bp) and non-coding RNA (ncRNA)). 
• Coding variants (frameshift, non-frameshift, start-loss, stop-loss, stop-
gain, splicing and missense). 
• Loss of function variants (frameshift, start-loss, stop-gain and splicing). 
SKAT-O tests were performed using two independent datasets as in 
below sections 1.2.2.2.1 and 1.2.2.2.2. 
1.2.2.2.1 IPDGC WES 
 
The sporadic PD WES data comprises 1,450 PD cases and 535 controls from 
IPDGC consortium, and 1,732 controls from the RSX1 WES data. Paired-end 
sequencing using Illumina HiSeq 2000 was performed for IPDGC and RSX1 data. 
The sequencing reads were aligned to the human reference genome (hg19) using 
BWA-MEM algorithm (Chang, Nguyen et al. 2010). Binary Alignment Map (BAM) 
files were generated using Picard tools (http://broadinstitute.github.io/picard). 
Further, SNPs and small insertions/deletions were called using Genome Analysis 
Toolkit (GATK) (McKenna, Hanna et al. 2010). The IPDGC and RSX1 datasets 
were merged by the joint variant calling of the g.VCF files. Genotype and variant 
quality control was performed using KGGSeq (Cingolani, Platts et al. 2012) and 
VCFtools (Danecek, Auton et al. 2011) as already mentioned in section 1.2.1.1. It 
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was followed by individual quality controls by excluding samples with gender 
inconsistencies, heterozygosity outliers, duplicate samples, individuals of 
divergent ancestry and missing genotype. After QC, the IPDGC-RSX1 dataset 
consists of 545,752 SNPs and 70,548 indels. The sequence-kernel association 
test (SKAT-O) was performed using EPACTS tool 
(https://genome.sph.umich.edu/wiki/EPACTS) to estimate the burden of rare 
variants in PD cases compared to controls. Association tests helps to understand 
the cumulative impact of rare variants in the candidate genes on PD risk.  
1.2.2.2.2 NeuroX 
 
The genotyping array NeuroX consists of 6,801 PD cases and 5,970 controls. The 
QC of this dataset was performed by excluding variants for subsequent analyses 
when the minimum call rate was less than 85%, a HWE p-value less than 1E-06 
in all the controls, or when the missingness rate was significantly different 
between cases and controls. Individuals with sex discordance, a heterozygosity 
rate of >3 standard deviations from the mean, more than 15% of missing 
genotypes, closely related to another individual in the dataset (>18.5%) or 
representing a population outlier after multi-dimensional scaling analysis, were 
removed from further analyses After QC, the data consists of 177,216 variants. 
Further, gene-based SKAT-O tests were performed to estimate the burden of rare 
variants in PD cases compared to controls. 
1.2.3 Development of Neurochip 
A genotyping array has been developed to verify our genetic findings in a diverse 
population. An Infinium iSelect Custom Genotyping Assay was designed in 
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collaboration with Illumina (www.illumina.org). This array has been designed as 
part of an international collaboration aiming to provide a new tool for the fine 
mapping and interrogation of various neurodegenerative diseases. This array 
was designed of the Illumina CoreExome 24+ v1.1 on the 24-sample format and 
has the following content: Illumina CoreExome 24+ v1.1 backbone, content from 
the original NeuroX array (Nalls, Bras et al. 2015), thorough review of known 
neurodegenerative disease genes for all coding/splice site variants reported in 
ExAC (http://exac.broadinstitute.org/), known pathogenic variants in each of 
these genes not found in ExAC, tagging SNPs to capture all common variation in 
these genes, additional novel content based on current and ongoing sequencing 
projects including WGS data of 180 samples and a full list of all GWAS hits in the 
NHGRI database. 
 The diseases covered by this array are Alzheimer’s disease (AD), 
Parkinson’s disease (PD), Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis 
(MS), Progressive Supranuclear Palsy (PSP), Cortical Basal Degeneration (CBD), 
Multiple System Atrophy (MSA), Frontotemporal Dementia (FTD), and Dementia 
with Lewy Bodies (DLB).  
1.2.4 Weighted Gene Co-expression Network analysis 
Co-expression of all the candidate genes from the discovery phase with 
Mendelian PD genes was investigated using publicly available RNA-sequencing 
data from postmortem human brain of 29 PD and 44 controls (Dumitriu, Golji et 
al. 2016). The weighted gene co-expression network was constructed using 
WGCNA (Langfelder and Horvath 2008) package in R. Modules are clusters of 
highly interconnected genes. Modules were identified using an unsigned 
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network with the power of 7 to achieve scale-free topology. However, we used 
unsigned co-expression network so that the modules correspond to clusters of 
genes with high absolute correlations. Each module is assigned a particular color. 
Gene significance (GS) represents a correlation between gene expression and 
trait (i.e. case/control status). Higher the absolute value of GSi, the more 
biologically significant is the ith gene (Langfelder and Horvath 2008). 
 The over-represented gene ontologies and KEGG pathways for all the 
genes in the modules were determined using HTSAnalyzeR package in R (Wang, 
Terfve et al. 2011), to facilitate biological interpretation. Over-representation 
analysis is performed based on the hypergeometric test (Subramanian, Tamayo 
et al. 2005). 
 
1.3 Results 
1.3.1 Discovery phase 
1.3.1.1 SNPs and INDELs 
 
Filtering of the variants by genotype and variant quality control resulted in 
17,072,717 SNPs and 4,322,295 indels across all samples. We investigated the 
families independently, and the variants were retained based on segregation 
among the family members. Moreover, only coding SNPs and indels with a minor 
allele frequency less than 1% were retrieved. Genes/variants were ranked on the 
basis of pathogenicity scores and their expression in brain.  
We identified mutations in genes causing PD and other forms of 
parkinsonism in some of the families. A novel stop-gain mutation was identified 
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in DJ1 (p. Q45*) in a Turkish family with an early-onset levodopa-responsive 
parkinsonism and signs of ALS (Hanagasi, Giri et al. 2016). In two Turkish 
families, a homozygous (p. R747W) (Giri, Guven et al. 2016) and compound 
heterozygous (p. A727T; p. C134) mutations in PLA2G6 were identified. A novel 
homozygous mutation in TREM2 (p. D86V) was identified in a Turkish family 
(figure 8 Turkey_PD240) with an autosomal recessive mode of inheritance (see 
table 2). The age at onset of the patient with the TREM2 mutation is 37 years, and 
he has dementia with parkinsonism. A point mutation was identified in LRRK2 
(p. I723V) in one of the Spanish family with an autosomal dominant mode of 
inheritance.  
 Apart from the known PD causal genes, we also identified some novel 
genes in multiple families. In Turkish family Turkish_PD326 (see figure 8) with 
the X-linked recessive mode of inheritance, the pathogenic (CADD score: 28.5) 
mutation (p. R102W) in SH3KBP1 is the only variant segregating in that family, 
and it was also identified in an early onset PD patient from an independent 
family in Rotterdam. The age at onset of the index-case from Turkish family 
(Turkish_PD326) is 40 years, and one year later he developed bradykinesia 
without resting or postural tremor. He has rapid eye movement (REM) sleep 
behavior disorder and levodopa treatment was effective for him.  
 In families with an autosomal dominant mode of inheritance rare 
heterozygous mutations in DYSF (p. Y1052C; p. T172M) (table 5) were identified 
in two Turkish families (figure 8 Turkey_PD291 and Turkey_PD314). Both these 
mutations are pathogenic with CADD scores as 27.2 and 27.9 respectively. In 
family Turkey_PD291, the age at onset of the PD patient is 44 years. He has right-
arm tremor and REM sleep behavior disorder. Brain MRI showed enlargement of 
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the retrocerebellar region. He showed improvement with levodopa treatment. 
The age at onset of the two PD patients from family Turkey_PD314 is 59 and 60 
years. In two families from the genetic isolate of the Netherlands and Spain, rare 
heterozygous mutations were identified in APC2 (p. S1584G; p. P946T; p. T104N) 
(table 5). The clinical details of the PD patients from these families are not 
available. 
 We identified some of the candidate genes, which are not identified in 
multiple families but are identified in sporadic PD data from replication cohort 
and will be discussed again in a replication phase (see table 4).  These candidate 
genes are HTT, CCNB3, CCDC154, CXorf22, MYO15A, TMEM63C and ULK2. A 
compound heterozygous mutation in HTT (p. P42T; p. P43Q) was identified in an 
Italian family (see figure 8 Italy_Fam034), and it is the only variant segregating 
in that family comprising 3 PD patients. In Turkish family (see figure 8 
Turkey_PD313) rare homozygous mutations in CCNB3 (p. M313I) and CCDC154 
(p. E133K), and in family Turkey_PD296 rare homozygous mutation in CXorf22 
(p. V547A) were identified. In a family from a genetic isolate of the Netherlands 
(see figure 8 GRIP252), a homozygous mutation in TMEM63C (p. R334H) was the 
most plausible one amongst the two variants segregating in that family. The 
variant p. R334H is pathogenic (CADD score: 24.5) and is present in the runs of 
homozygosity. A compound heterozygous mutation in MYO15A (p. L3160F; p. 
R201H) was identified in a Spanish family (figure 8 Spain_2933). Only two 
variants are segregating in this family comprising two PD patients. Furthermore, 
a rare homozygous stop-loss mutation in ULK2 (p. *170G) was identified in a 
Tunisian family (figure 8 Tunisia_3086), and it is the only mutation segregating 
in that family with 2 PD patients. 
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Table 2: SNVs identified in genes causing parkinsonism and other neurological disorders. 
Cohort 
Famil
y 
Typ
e 
CHR RefGene_Features gnomAD 
Turkey PD262 AH 
22:38508548:G/
A 
PLA2G6:NM_001199562:c.2239C>T:p.R747W:(16Exo
ns):exon15:missense 
0.00000899
4 
Turkey PD295 AH 1:8025426:C/T 
PARK7:NM_001123377:c.133C>T:p.Q45*: 
(7Exons):exon3:stopgain 
N 
Turkey PD240 AH 6:41129135:T/A 
TREM2:NM_018965:c.257A>T:p.D86V:(5Exons):exon2
:missense 
N 
Turkey PD328 CH 
22:38508248:C/
T 
PLA2G6:NM_001199562:c.2179G>A:p.A727T:(16Exon
s):exon16:missense 
0.000222 
Turkey PD328 CH 
22:38541467:AG
/A- 
PLA2G6:NM_001199562:c.?400del-
C:p.C134:(16Exons):exon3:frameshift; 
N 
Turkey PD270 AH 
6:161969884:AC
/A- 
PARK2:NM_004562:c.1082+1GT>-
T:(12Exons):exon9GTdonor 
N 
Spain HCB3 Het 
12:40671989:A/
G 
LRRK2: NM_198578:c.2167A>G: 
p.I723V:exon18:missense 
0.04 
* AH: Alternative Homozygous; CH: Compound Heterozygous; Het: Heterozygous; CHR: Chromosome. 
 
 
 
1.3.1.2 Structural variants/Copy number variants 
 
The SVs and CNVs were called for all the 180 WGS samples. The total number of 
losses and gains after removing regions such as centromeres, telomeres, 
immunoglobulin, gap locations, repeat masked regions, GC percent greater than 
90 and less than 10, common CNVs from Database of Genomic Variants (DGV) 
and low mappable regions are illustrated in table 3. Further, all the SVs and 
CNVs, which are segregating among the family members and are confirmed after 
visualization in IGV were retrieved.  
 Copy number variants such as homozygous deletion of exon1 to exon5 in 
DJ1 (Bonifati, Rizzu et al. 2003) and duplication in PARK2 were identified in 
families from the genetic isolate of the Netherlands (table 10). All the CNVs, 
which are segregating in the families and were confirmed after IGV visualization 
are mentioned in table 10. After filtering the common SVs from DGV, we were 
not left with any SVs segregating in the families from all the cohorts. 
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Table 3: Copy Number Variants in all cohorts. 
Cohort Deletions after filtering Duplications after filtering 
Dutch 58 188 
GRIP 631 4213 
Italian 477 1397 
Portugal 167 541 
Spanish 257 777 
Tunisian 144 432 
Turkish 363 863 
 
1.3.2 Replication 
1.3.2.1 Gene identification in sporadic PD WES dataset 
 
The prioritized variants/genes from discovery cohort were investigated in WES 
data from PDGSC. After screening the candidate genes from discovery cohort 
families with an autosomal recessive and compound heterozygous mode of 
inheritance, we identified 8 genes (with different variants), namely HTT, CCNB3, 
CCDC154, CXorf22, MYO15A, SH3KBP1, TMEM63C and ULK2 in PDGSC data. The 
detailed description of these variants, their features and minor allele frequency 
is mentioned in table 4. 
 In the sporadic PD data from PDGSC, 9 PD patients carry hemizygous and 
1 patient carries an alternative homozygous mutation in SH3KBP1 (figure 4). All 
these variants in SH3KBP1 have MAF less than 1% (table 4) in public databases 
such as ExAC, gnomAD and 1000 genomes. One PD patient carries a rare 
alternative homozygous mutation in HTT (p. Q38P). The frequency of this 
missense mutation in gnomAD browser is 0.01. Furthermore, 8 PD patients carry 
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rare hemizygous mutations in CCNB3, and 2 PD patients carry an alternative 
homozygous mutation in CCDC154. Alternative homozygous missense mutations 
in TMEM63C (p. R334H and p. P5S) were identified in two PD patients. A p. 
R334H variant in TMEM63C was also identified in a family (figure 8 GRIP252) 
from discovery cohort. An alternative homozygous mutation in MYO15A (p. 
R2942C) and ULK2 (p. D500A) were identified in single PD patient, respectively 
(table 4). All these variants identified in PDGSC data are exclusively present in 
the PD cases. 
 DYSF and APC2, which replicated in multiple dominant families, were 
screened in sporadic PD data. A rare (MAF<0.01) heterozygous mutations in 
DYSF were identified exclusively in 23 PD patients from the sporadic data (figure 
5). Furthermore, 12 sporadic PD patients carry rare heterozygous mutations in 
APC2 (figure 6) (see table 5).  
 
 
 
 
Figure 4: Mutations in SH3KBP1. Variants highlighted in blue rectangles are identified in 
two families and the rest other variants are identified in sporadic PD WES data. 
 
 
Figure 5: Mutations in DYSF. Variants highlighted in blue rectangles are identified in two 
families and the rest other variants are identified in sporadic PD WES data.  
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Figure 6: Mutations in APC2. Variants highlighted in blue rectangles are identified in three 
families and the rest other variants are identified in sporadic PD WES data. 
 
1.3.2.2 Association analysis using two independent datasets 
 
WES data from 1,450 sporadic PD cases and 2,267 controls from the IPDGC 
consortium and RSX1 as well as NeuroX genotyping data from 6,801 sporadic PD 
cases and 5,970 controls were used to estimate the genetic burden of rare 
variants in candidate genes identified in the discovery cohort. We performed 
gene-based SKAT-O tests using both these datasets. We used four criteria to see 
the enrichment of rare variants. The first criteria showed the burden of all rare 
variants in the respective genes, secondly to see an enrichment of functional 
variants and followed by coding and loss of function variants.  
 In the first replication cohort of sporadic PD WES data, the gene-based 
association tests showed that loss of function variants in STON1-GTF2A1L 
(Pvalue: 0.0001) and IGFN1 (Pvalue: 0.01) are enriched to PD. Moreover, all the 
rare variants in ULK2 (Pvalue: 0.01) show gene-based association to PD risk 
(table 6). 
 In the second independent dataset of a genotyping array, i.e. NeuroX, 
gene-based association shows that coding variants in ULK2 (Pvalue: 0.001) and 
IGFN1 (Pvalue: 0.002) are enriched to PD. Further, rare variants in KNTC1 
(Pvalue: 0.00001) and MFSD8 (Pvalue: 0.007) are also associated with PD risk 
(table 7).  
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Table 4: Genes identified in AR families (discovery cohort) along with their replication.  
Discovery cohort Replication cohort 
Cohort Family Type Gene chr:pos Genefeature gnom
AD 
Variants_in_PDGSC (No. of 
carriers) 
Italy Fam-
034 
CH HTT 4:3076671:C/A ; 
4:3076674:C/A 
NM_002111:c.124
C>A:p.P42T:misse
nse ; 
NM_002111:c.128
C>A:p.P43Q:misse
nse 
0.0006 ; 
0.0005 
HTT:NM_002111:c.119A>C:p.Q38P:mis
sense (1) 
Turkey PD326 AH SH3KBP
1 
X:19725085:G/A NM_031892:c.304
C>T:p.R102W:miss
ense 
N SH3KBP1:NM_031892:c.1775G>A:p.G5
92D:missense (1); 
SH3KBP1:NM_031892:c.1681G>A:p.G5
61S:missense (4); 
SH3KBP1:NM_031892:c.1061C>T:p.T3
54I:missense (1); 
SH3KBP1:NM_031892:c.910G>A:p.V30
4I:missense (1); 
SH3KBP1:NM_031892:c.716C>T:p.P23
9L:missense (1); 
SH3KBP1:NM_031892:c.415G>A:p.V13
9I:missense (1); 
SH3KBP1:NM_031892:c.301C>T:p.R10
1C:missense (1) 
Turkey PD313 AH CCNB3 X:50052108:G/A CCNB3:NM_03303
1:c.939G>A:p.M31
3I:missense 
N CCNB3:NM_033031:c.290C>T:p.T97I:m
issense (1) ; 
CCNB3:NM_033031:c.1712G>A:p.R571
K:missense (1); 
CCNB3:NM_033031:c.2939C>T:p.T980I
:missense (1); 
CCNB3:NM_033031:c.3059C>T:p.T102
0I:missense (1); 
CCNB3:NM_033031:c.3796C>T:p.R126
6C:missense (1); 
CCNB3:NM_033031:c.2876A>G:p.E959
G:missense (1);  
CCNB3:NM_033031:c.2419G>A:p.E807
K:missense (1); 
CCNB3:NM_033670:c.216G>T:p.E72D:
missense (1) 
Turkey PD313 AH CCDC15
4 
16:1493524:C/T CCDC154:NM_001
143980:c.397G>A:
p.E133K:missense 
0.00002 CCDC154:NM_001143980:c.1151T>G:p
.L384R:missense (1); 
CCDC154:NM_001143980:c.1124G>A:p
.R375Q:missense (1) 
Turkey PD296 AH CXorf22 X:35985775:T/C CXorf22:NM_1526
32:c.1640T>C:p.V5
47A:missense 
N CXorf22:NM_152632:c.1665G>T:p.K55
5N:missense (1); 
CXorf22:NM_152632:c.T2856del-
C:p.F952:frameshift (1) 
GRIP_NL GRIP25
2 
AH TMEM6
3C 
14:77706888:G/
A 
TMEM63C:NM_02
0431:c.1001G>A:p.
R334H:missense 
0.002 TMEM63C:NM_020431:c.1001G>A:p.R
334H:missense (1); 
TMEM63C:NM_020431:c.13C>T:p.P5S:
missense (1) 
Spain 2933 CH MYO15A 17:18064722:C/
T ; 
17:18075051:G/
A 
MYO15A:NM_0162
39:c.9478C>T:p.L3
160F:missense ; 
ENST0000057984
8:c.602G>A:p.R20
1H:missense 
0.006; 
0.006 
MYO15A:NM_016239:c.8824C>T:p.R29
42C:missense (1) 
Tunisia 3086 AH ULK2 17:19685288:A/
C 
ENST0000057543
2:c.508T>G:p.*170
G:stoploss 
0.0003 ULK2:NM_001142610:c.1499A>C:p.D5
00A:missense (1) 
* AH: Alternative Homozygous; CH: Compound Heterozygous 
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 Table 5: Genes identified in multiple AD families (discovery cohort) along with their replication. 
Discovery cohort Replication cohort 
Cohor
t 
Family Type Gene chr:pos Genefeature gnomAD Variants_in_PDGSC (No. of 
carriers) 
Turkey PD291 ; 
PD314 
Het DYSF 2:71797798:
A/G ; 
2:71740427:
C/T 
DYSF:NM_00113
0987:c.3155A>G
:p.Y1052C:misse
nse ; 
DYSF:NM_00113
0980:c.515C>T:
p.T172M:missen
se 
N ; 0.00004 DYSF:NM_001130986:c.1624C>T:p.R542
W:missense  (1); 
DYSF:NM_001130986:c.1625G>A:p.R542
Q:missense (1); 
DYSF:NM_001130986:c.1861A>G:p.T621
A:missense (1); 
DYSF:NM_001130986:c.2389C>T:p.P797
S:missense (1); 
DYSF:NM_001130986:c.2762C>T:p.P921
L:missense  (1); 
DYSF:NM_001130986:c.2909A>C:p.K970
T:missense  (1); 
DYSF:NM_001130986:c.2960C>T:p.S987
F:missense  (1); 
DYSF:NM_001130986:c.3074G>A:p.R102
5Q:missense (1) ; 
DYSF:NM_001130986:c.3448G>A:p.D115
0N:missense  (1); 
DYSF:NM_001130986:c.3623C>T:p.P120
8L:missense (1); 
DYSF:NM_001130986:c.3685C>T:p.R122
9C:missense (1); 
DYSF:NM_001130986:c.4042T>C:p.C134
8R:missense (1); 
DYSF:NM_001130986:c.4168G>A:p.V139
0I:missense (1); 
DYSF:NM_001130986:c.4186C>T:p.R139
6C:missense (1); 
DYSF:NM_001130986:c.5099C>T:p.A170
0V:missense (1); 
DYSF:NM_001130986:c.5120G>A:p.R170
7H:missense  (1); 
DYSF:NM_001130986:c.5371A>C:p.T179
1P:missense  (3); 
DYSF:NM_001130986:c.5377C>T:p.R179
3W:missense  (1); 
DYSF:NM_001130986:c.5378G>A:p.R179
3Q:missense  (1); 
DYSF:NM_001130986:c.5752C>T:p.R191
8C:missense  (1); 
DYSF:NM_001130986:c.6176C>T:p.A205
9V:missense (1) 
GRIP_N
L ; 
Spain 
GRIP104 
; 
GRIP251 
; 
SpainHC
B1 
Het APC2 19:1468050:
A/G ; 
19:1466136:
C/A ; 
19:1453508:
C/A 
APC2:NM_00588
3:c.4750A>G:p.S
1584G:missense 
; 
APC2:NM_00588
3:c.2836C>A:p.P
946T:missense ; 
APC2:NM_00588
3:c.311C>A:p.T1
04N:missense 
0.00002; 
0.00006; N 
APC2:NM_005883:c.304G>A:p.A102T:mis
sense  (1); 
APC2:NM_005883:c.1628G>A:p.R543Q:m
issense  (1); 
APC2:NM_005883:c.1796G>A:p.S599N:m
issense  (1); 
APC2:NM_005883:c.3019G>A:p.G1007S:(
15Exons):exon15:missense  (2); 
APC2:NM_005883:c.4067G>T:p.R1356L:
missense  (1); 
APC2:NM_005883:c.4826A>T:p.D1609V:
missense (1) ; 
APC2:NM_005883:c.5246G>A:p.R1749Q:
missense  (1); 
APC2:NM_005883:c.5270C>T:p.A1757V:
missense  (1); 
APC2:NM_005883:c.5359G>A:p.V1787M:
missense  (1); 
APC2:NM_005883:c.5613C>*:p.T1871?:m
issense (2) 
*Het: Heterozygous. 
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Table 6: Gene-based SKAT-O results of IPDGC exomes. 
Gene Nallrare Pallrare Pfunctional Pcoding Plof 
APC2 22 0.04212 0.6078 0.6078 0.886927 
BCHE 22 0.53183 0.51342 0.51342 8.0289e-18 
CCDC129 81 0.33386 0.72253 0.72253 0.34602 
CCDC154 23 1 0.66855 0.3398 0.2576 
CCNB3 33 0.2299 0.45247 0.43821 0.75588 
CRYZL1 15 0.86234 1 1 0.70161 
CXorf22 31 0.81821 0.6444 0.6444 0.45899 
DHX57 130 0.60213 0.70882 0.70882 0.83013 
DYSF 220 0.28941 0.22977 0.27635 0.18173 
DPP8 63 0.00040823 0.0011138 0.028692 0.7507 
EPC1 22 0.016828 0.10013 0.10013 0.44955 
FCF1 25 0.042565 0.031926 0.24796 0.78398 
GART 81 0.011433 0.096183 0.08225 1 
HTT 201 0.21039 0.054938 0.054938 1 
IGFN1 225 0.46065 0.3122 0.35503 0.011291 
KNTC1 90 0.23592 0.22598 0.22598 0.9097 
MFSD8 26 1 0.89005 1 0.53128 
MYO15A 179 0.5211 0.66788 0.66788 0.71526 
PHKA2 55 0.029669 0.011683 0.011259 0.0052439 
RPA2 18 0.27994 0.23606 0.23428 0.045132 
SH3KBP1 34 0.7216 0.51781 0.51781 0.53622 
SHANK2 119 0.0042875 0.044719 0.044719 0.51904 
SLC22A10 65 0.20036 0.65099 0.65099 1 
SLC45A3 20 0.89859 0.55154 0.55154 0.66004 
STON1-GTF2A1L 65 0.027945 0.0019625 0.0024822 0.0001976 
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TBX4 21 0.43582 0.6483 0.6483 5.8597e-05 
TMEM63C 62 1 1 1 0.23493 
TTLL12 75 0.72034 0.81071 0.89576 1 
ULK2 58 0.08077 0.018658 0.018658 0.11045 
WWC1 89 0.75591 0.43159 0.54367 1 
ZNF518A 53 0.27601 0.27601 0.27601 NA 
ZNF521 55 0.60031 0.58536 0.56885 2.1233e-05 
* Nallrare: Number of all rare variants; Pallrare: P-value for all rare variants; Pfunctional: P-value for functional 
variants; Pcoding:P-value for coding variants; Plof: P-value for loss of function variants. 
 
 
Table 7: Gene-based SKAT-O results of NeuroX. 
Gene Nallrare Pallrare Pfunctional Pcoding Plof 
APC2 7 0.16965 0.16965 0.16965 NA 
BCHE 9 0.12471 0.12471 0.12471 NA 
CCDC129 21 0.062061 0.037296 0.037296 NA 
CCDC154 15 1 0.88392 0.88392 0.90874 
CRYZL1 6 0.015284 0.015284 0.015284 NA 
DHX57 24 0.01116 0.01116 0.01116 0.9148 
DYSF 71 0.56924 0.56508 0.56508 NA 
DPP8 10 0.62937 0.62937 0.62937 NA 
EPC1 9 0.79752 0.78971 0.78971 NA 
FCF1 2 0.17167 0.17167 0.17167 NA 
GART 16 0.52262 0.52463 0.52463 NA 
HTT 33 0.73869 0.73869 0.73869 NA 
IGFN1 56 0.012481 0.0022045 0.0022045 0.20873 
KNTC1 30 1.4171e-05 1.4171e-05 1.4171e-05 0.39821 
MFSD8 14 0.0072169 0.0072169 0.0072169 NA 
MYO15A 73 0.42765 0.44825 0.44825 NA 
RPA2 3 0.76321 0.76321 0.76321 NA 
SHANK2 31 0.69882 0.8667 0.8667 NA 
SLC22A10 19 0.13099 0.13099 0.13099 0.049742 
 58 
SLC45A3 13 0.00097305 0.00097305 0.00097305 NA 
STON1-GTF2A1L 33 0.76908 0.56707 0.56707 0.3325 
TBX4 8 0.84568 1 1 NA 
TMEM63C 11 0.054963 0.066453 0.066453 NA 
TTLL12 18 0.00066903 0.00066903 0.00066903 NA 
ULK2 14 0.0011033 0.0016626 0.0016626 NA 
WWC1 21 0.011888 0.011888 0.011888 NA 
ZNF518A 24 0.0028038 0.0028038 0.0028038 NA 
ZNF521 13 0.30372 0.30372 0.30372 NA 
* Nallrare: Number of all rare variants; Pallrare: P-value for all rare variants; Pfunctional: P-value for functional 
variants; Pcoding: P-value for coding variants; Plof: P-value for loss of function variants. 
 
 
 
 
1.3.3 Development of Neurochip 
 
In the context of WGS performed in this study, we have submitted a total of 
25,383 variants to Illumina (table 8). In brief, all the segregating variants that 
surpassed our QC filters have been selected for inclusion in the mentioned array. 
Additionally, variation in ClinVar (http://www.ncbi.nlm.nih.gov/clinvar/), as 
well as a rare variation (MAF < 0.01) in ExAC and an in-house database of 1,500 
PD cases and 500 controls (IPDGC WES project) from the most interesting genes 
were included in this array. Variants of interest derived from WES efforts of 
other consortium partners, as well as variants needed for the Mendelian 
randomization and gene-environment interaction analyses, have also been 
selected for this array.  
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Table 8: List of variants selected from the WGS efforts for Neurochip. 
Source Number of variants 
WGS segregating variants 1,180 
Genes of interest: ClinVar 1,183 
Genes of interest: ExAC 22,119 
Genes of interest: IPDGC exomes 901 
Total 25,383 
1.3.4 WGCNA 
 
In order to construct the weighted gene co-expression network, we need to 
choose the soft thresholding power β to which co-expression similarity is raised 
to calculate adjacency. The soft thresholding power is chosen based on the 
criterion of approximate scale-free topology. We chose the power 7, which is the 
lowest power for which the scale-free topology fit index curve flattens out upon 
reaching a high value (in this case 0.80) (figure 7). 
 
 
Figure 7: Analysis of network topology for various soft-thresholding powers. The figure 
shows the scale-free fit index (y-axis) as a function of the soft thresholding power (x-axis).  
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We would like to identify modules that are significantly associated with the 
measured clinical traits. A summary profile (eigengene) for each module was 
generated using WGCNA package in R, later we correlate eigengenes with 
external traits and look for the most significant associations. 
 WGCNA results for all the candidates from the discovery phase data are 
illustrated in table 11. Some of the candidate genes from the families (discovery 
cohort), which are co-expressed with PD causal genes are discussed as follows: 
we observed that the candidate gene TMEM86B is co-expressed with LRRK2 in a 
blue module comprising 1503 genes. The blue module is positively correlated to 
the trait with a significant P-value of 0.001. Among the KEGG pathways, 
mitophagy and mTOR signaling pathway are over-represented in this module 
(table 9). 
 In a turquoise module, which consists of 2580 genes, CCDC154, ZNF766 
and VPS35 are co-expressed with PARK2. The turquoise module is negatively 
correlated to the trait with a significant P-value of 1e-04. In this module 
regulation of postsynaptic membrane potential, synaptic plasticity and 
macroautophagy are over-represented (table 9).  
  APC2 is co-expressed with PINK1 in a grey60 module, but this module is 
not significantly correlated to the trait. Furthermore, DYSF and CCNB3 are co-
expressed with FBXO7 in a pink module. Although this module is not significantly 
correlated to the trait, clathrin-dependent endocytosis and regulation of 
apoptotic process are over-represented (table 9). 
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Table 9: Module-trait correlation and over-represented pathways and Gene ontology 
* Cor.Module.trait: Correlation of module and trait. 
 
1.4 Discussion 
 
In this study, analysis of WGS/WES data as discovery cohort of individuals with 
familial PD has led to the identification of mutations in already known PD causal 
genes such as LRRK2, DJ1 and PARK2. A variant in PLA2G6 was identified in a 
patient with early-onset parkinsonism, and the results confirm the clinical 
heterogeneity of PLA2G6-associated neurodegeneration. A novel alternative 
homozygous mutation in TREM2 was identified in a patient with dementia and 
parkinsonism.  
 Exome sequencing of patients with PD helped to identify hemizygous 
mutations in SH3KBP1 in two probands from unrelated families. Moreover, after 
screening the large repository of WES data from PDGSC consortium, we 
identified 7 missense mutations with MAF less than 1% in SH3KBP1 in 10 
sporadic PD cases. SH3KBP1 is involved in many cellular processes such as 
down-regulation of receptor tyrosine kinase and apoptosis (Narita, Nishimura et 
Gene Module Cor.Module.trait Pvalue Over-represented Pathways & GO 
TMEM86B 
blue 0.37 0.001 mTOR signaling pathway ; mitophagy 
LRRK2 
APC2 
grey60 -0.061 0.6 GTPase activity 
PINK1 
CCNB3 
pink 0.07 0.5 
Clathrin-dependent endocytosis ; regulation of 
apoptotic process DYSF 
FBXO7 
CCDC154 
turquoise -0.44 1e-04 
Chemical synaptic transmission ; regulation of 
postsynaptic membrane potential ; regulation of 
synaptic plasticity ; regulation of macroautophagy 
VPS35 
PARK2 
ZNF766 
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al. 2005, Bian, Yu et al. 2008). Previous studies have already reported 
inflammatory reaction and apoptosis as major causes of PD (Blesa, Trigo-Damas 
et al. 2015). Moreover, SH3KBP1 is involved in pathways such as Clathrin-
mediated endocytosis and vesicle-mediated transport or membrane trafficking. 
PD is defined by loss of dopaminergic neurons in the substantia nigra and 
dysfunction of the dopaminergic synapse heralds trafficking impairment. Hence, 
SH3KBP1 looks like a promising candidate and might contribute to PD 
pathogenesis.  
 Apart from this gene, there are six more genes identified in discovery 
cohort families with AR mode of inheritance, which are not replicated in multiple 
families but are identified in a large WES data of sporadic PD. These genes are 
HTT, CCDC154, CXorf22, TMEM63C, MYO15A and ULK2. Non-synonymous and 
loss of functions variants with MAF less than 1% were identified in these 6 
replicating genes.  
The first gene HTT (Huntingtin) is linked to neurodegenerative disease 
Huntington’s disease and is involved in biological processes such as retrograde 
vesicle-mediated transport- Golgi to ER, apoptotic process and positive 
regulation of mitophagy (Schulte and Littleton 2011). Several lines of evidence 
have shown that PARK2/PINK1 pathway plays a critical role in the autophagic 
removal of damaged mitochondria, i.e. mitophagy and defects in mitophagy 
cause impaired motor coordination, tremor and the accumulation of protein 
aggregates/inclusion bodies in residual neurons (Jin and Youle 2012). Hence, 
HTT seems like an interesting gene, but of course we need replication in more 
families to confirm it as a PD causal gene.  
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Molecular function and pathways for the second gene CCDC154 are not 
known. As per the performed weighted gene co-expression network analysis, it 
is observed that CCDC154 is co-expressed with PD Mendelian gene PARK2. The 
third gene TMEM63C is involved in calcium-activated cation channel activity 
(Hou, Tian et al. 2014). As per experimental evidence of Affinity Capture-Mass 
spectrometry TMEM63C interacts with NDUFB8 (NADH: Ubiquinone 
Oxidoreductase Subunit B8), i.e. Complex I. Previous published studies have 
suggested mild defects of complex I in PD (Swerdlow, Parks et al. 1996, Schapira 
1998). Furthermore, Myosins (MYO15A) are actin-based motor molecules with 
ATP activity. Mutations in this gene are associated with congenital, 
neurosensory, nonsyndromal deafness (Kalay, Uzumcu et al. 2007). Another 
promising candidate ULK2 (Unc-51 Like Autophagy Activating Kinase 2) is 
involved in regulation of autophagy and mTOR signaling pathway (Jung, Seo et al. 
2011, Lee and Tournier 2011). Autophagy is associated with the pathogenesis of 
Dementia with Lewy bodies and PD. Alteration of upstream autophagy-related 
proteins like ULK2 has been observed in Lewy body disease (Miki, Tanji et al. 
2016). In the gene-based sequence kernel association tests using both 
independent datasets from replication cohort, we observed a significant 
association of rare variants in ULK2 to PD. 
We identified rare heterozygous mutations in DYSF and APC2 in multiple 
families with an autosomal dominant mode of inheritance. These genes were 
replicated further in sporadic PD data from PDGSC consortium. Dysferlin (DYSF) 
plays a significant role as calcium ion sensor and is involved in calcium ion 
triggered fusion of synaptic vesicle to plasma membrane (Fuson, Rice et al. 
2014). The protein encoded by APC2 helps to recruit, phosphorylates and targets 
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beta-catenin for ubiquitylation and proteasomal degradation (Nakagawa, Murata 
et al. 1998). Failure of ubiquitin-proteasome system has been identified in 
familial PD cases (McNaught, Olanow et al. 2001). APC2 is involved in the PI3K-
Akt signaling pathway.  
Approximately 25,383 variants from this study were submitted to Illumina 
for the development of genotyping array Neurochip. In this study, we identified 
promising candidate genes using NGS data, but in the future validation of these 
risk variants using the Neurochip, i.e. a genotyping array has to be performed. 
Furthermore, some functional validation using cellular or experimental animal 
model has to be done to prioritize genes for further investigation.  
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Figure 8: Pedigrees of families from discovery cohort. 
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Table 10: CNVs segregating in families from discovery cohort. 
Cohort sample 
Poisson 
score 
Copy 
Number 
Chr Start End Size Genes Feature 
GRIP D98-8553 1974.52 3 6 162204001 162439000 234999 PARK2 coding 
GRIP 
D98-8239, 
D98-8240 
585 0 1 8018803 8032836 14033 PARK7 coding 
GRIP D98-8467 705.59 1 5 175791240 175817819 26579 
HIGD2A; 
ARL10 ; NOP16 
; MIR1271 
coding 
GRIP D98-8518 290.54 1 X 100213960 100227254 13294 ARL13A 5UTR 
GRIP D98-8541 521.5 1 7 66459649 66476339 16690 SBDS ; TYW1 coding 
GRIP D98-8623 185.06 1 2 56389768 56400376 10608 RP11-481J13.1 ncRNA 
Italian L-0174 141.88 1 11 76989993 76996482 6489 GDPD4 coding 
Italian L-0200 137.59 1 11 76989993 76996482 6489 GDPD4 coding 
Italian L-0264 140.99 1 11 76989993 76996482 6489 GDPD4 coding 
Italian F1326 130.62 1 16 67851933 67857174 5241 TSNAXIP1 coding 
Italian G-1261 284.41 1 1 245695557 245708504 12947 KIF26B coding 
Italian P-0152 175.56 0 8 11708729 11714635 5906 CTSB coding 
Italian R-0499 148.96 1 11 102209308 102215813 6505 BIRC3 coding 
Italian S-0074 269.75 1 1 242034087 242045637 11550 EXO1 coding 
Italian S-0074 217.12 1 4 152348381 152358593 10212 FAM160A1 coding 
Portugal 
1701195-
71237 
390.81 1 3 182179588 182196930 17342 
RP11-139K4.1 ; 
FLJ46066 
coding 
Portugal 
19120-
75116 
69.18 1 17 5273006 5275761 2755 RP11-420A6.2 coding 
Portugal 
19120-
75116 
397.18 0 19 48271007 48278181 7174 
CTD-
2571L23.6 
coding 
Portugal 
19120-
75116 
520.17 1 22 32857793 32879303 21510 BPIFC ; FBXO7 coding 
Portugal 
367127102-
20604 
67.42 1 10 60995095 60997893 2798 PHYHIPL coding 
Portugal 
367127102-
20604 
98.81 1 3 17741869 17746005 4136 TBC1D5 Intron 
GRIP D98-8225 214.11 3 4 146612001 146642000 29999 C4orf51 coding 
GRIP D98-8400 411.31 3 12 122999001 123077000 77999 KNTC1 ; RSRC2 coding 
GRIP D98-8463 527.5 3 7 107935001 107998000 62999 NRCAM coding 
GRIP D98-8541 140.68 3 X 116081001 116099000 17999 SETP8 coding 
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GRIP D98-8549 37.52 4 19 57776001 57782000 5999 
ZNF805 ; CTC-
444N24.8 
downstream 
GRIP D98-8553 1974.52 3 6 162204001 162439000 234999 PARK2 coding 
GRIP D98-8558 45.29 3 19 4800001 4810000 9999 
FEM1A ; 
AC005523.2 
downstream 
GRIP D98-8558 61.05 3 2 55441001 55450000 8999 CLHC1 coding 
GRIP D98-8623 122.96 3 X 46315001 46337000 21999 KRBOX4 coding 
GRIP D98-8624 319.08 3 1 185095001 185132000 36999 
TRMT1L ; 
SWT1 
coding 
GRIP D98-8624 18.98 3 17 17122001 17126000 3999 FLCN coding 
GRIP D98-8656 513.6 3 1 8077001 8152000 74999 
ERRFI1 ; CTA-
215D11.4 ; 
RP11-
431K24.1 
5UTR 
GRIP D98-8735 588.91 3 7 107935001 107999000 63999 NRCAM coding 
Turkish PD296-3 1045.7 3 5 24437001 24544000 106999 CDH10 coding 
Turkish PD300-4 78.44 3 12 15063001 15074000 10999 
ERP27 ; 
C12orf60 
coding 
Turkish PD300-5 65.9 3 12 15063001 15075000 11999 
ERP27 ; 
C12orf60 
coding 
Turkish PD313-3 2142.05 3 16 60543001 60780000 236999 
GNPATP 
;RP11-
354I13.1 
coding 
Turkish PD317-11 240.78 3 9 14064001 14094000 29999 NFIB coding 
Turkish PD317-4 280.78 3 9 14064001 14095000 30999 NFIB coding 
Turkish PD317-8 247.92 3 9 14064001 14095000 30999 NFIB coding 
Italian F1326 62.93 3 6 24373001 24385000 11999 
DCDC2 ; 
LOC285819 
5UTR 
Italian G-1261 645.05 3 X 33790001 33869000 78999 
RP11-305F18.1 
; 
LOC105373153 
Intron 
Italian M0160 17.75 4 6 41931001 41933000 1999 CCND3 ; BYSL Intron 
Italian M-1249 90.24 3 8 90061001 90071000 9999 CALB1 coding 
Italian P-1806 85.34 3 4 125682001 125694000 11999 NUP58P1 coding 
Portugal 
1514090-
93542 
1327.91 3 22 29355001 29504000 148999 ZNRF3 coding 
Portugal 
1701195-
71237 
24.98 3 16 57050001 57054000 3999 NLRC5 coding 
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Table 11: WGCNA results for candidate genes from autosomal recessive and dominant 
families. 
Gene Module GS.status Pvalue.GS 
OTOGL black -0.3390497667 0.0033431297 
SLC22A10 black -0.2586661437 0.0271292791 
FRAS1 black -0.2227132816 0.0582407541 
TOX black -0.1429340601 0.2276800382 
TMEM86B blue 0.3757306037 0.0010538326 
WBP4 blue -0.3604966845 0.001730364 
CCDC22 blue 0.3221938414 0.0054382815 
DNAH9 blue -0.2970224943 0.0107158678 
SPEF2 blue -0.2846376596 0.0146593845 
SYTL5 blue -0.2820478636 0.0156263661 
TRIM68 blue 0.2431537282 0.0381843914 
LRRK2 blue -0.2269477618 0.0535015257 
TRMT2A blue 0.172252417 0.145050002 
MAGIX blue 0.0069715163 0.9533206673 
SLC3A2 brown 0.6086642776 1.111321607394E-008 
MFSD8 brown -0.4607603161 4.0951370913064E-005 
PRKDC brown -0.430762044 0.0001422426 
KNTC1 brown -0.3363285063 0.0036228854 
ZBTB38 brown -0.1203456047 0.3104978349 
PARD3 cyan 0.5038537839 5.51294722264513E-006 
WWC1 cyan 0.2713719203 0.0202142416 
GPR143 cyan 0.2129128232 0.0705243791 
PCSK5 cyan 0.1158287278 0.3291389848 
ZNF837 darkgreen -0.0398157252 0.7380424046 
ARVCF darkred 0.0428104806 0.7191278193 
OBSCN darkred 0.0192977455 0.8712670539 
NEB darkred -0.0142479142 0.9047689923 
SH3KBP1 darkturquoise -0.1677937499 0.1559081526 
RNF212 darkturquoise 0.036621944 0.7583862074 
MAST3 darkturquoise 0.0210184253 0.8599000262 
TCIRG1 green 0.5652909783 1.88282956042321E-007 
TREM2 green 0.4500623614 6.4702821095638E-005 
AKR1C3 green 0.3871920713 0.000714115 
AHNAK green 0.3867607486 0.0007248349 
ADAMTS9 green 0.3638942997 0.0015523936 
GART greenyellow -0.4336660898 0.0001267233 
HEXA greenyellow -0.417645092 0.0002366419 
ULK2 greenyellow -0.3763425176 0.0010325286 
FAM186A greenyellow 0.3661514476 0.0014434631 
MTMR2 greenyellow -0.2147149102 0.0681216872 
APC2 grey60 0.2210446139 0.0601996821 
BCHE grey60 -0.1568755363 0.1850271116 
PINK1 grey60 -0.0937253383 0.4302835512 
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EPC1 lightcyan 0.265715492 0.0230803996 
GBA lightgreen -0.3669296043 0.0014075385 
PLA2G6 lightyellow 0.1217650028 0.304783699 
AHI1 magenta -0.4702892927 2.68946076723436E-005 
SPHKAP magenta -0.4097714916 0.0003180653 
DCHS2 magenta -0.2484990311 0.0340139339 
DOCK5 pink 0.2521478141 0.0313916937 
CCNB3 pink -0.2373083406 0.0432234204 
DYSF pink 0.214126626 0.0688986853 
SLC45A3 pink 0.1743673621 0.1401022353 
PLD1 pink 0.0995506435 0.4020504048 
LRP2 pink 0.0835177903 0.4823743401 
ZNF536 pink -0.0752168871 0.5270875213 
FBXO7 pink -0.0738983522 0.5343755328 
MAMLD1 pink 0.0168930267 0.8871961225 
CRYZL1 purple -0.485664752 1.32843176942749E-005 
HCFC1 purple 0.3581667636 0.0018628058 
ACACB purple 0.3360473124 0.0036529486 
RPA2 purple -0.2114762178 0.0724881179 
MAPKBP1 purple 0.1734501152 0.1422322327 
DCAF10 purple -0.1644919037 0.1643299994 
CAAP1 purple -0.0974746604 0.4119848622 
PLEKHA6 red -0.1193277341 0.3146378516 
SBF1 red 0.0621563031 0.6013896255 
ZNF521 royalblue -0.1699201962 0.1506566768 
LAMC3 salmon 0.3806669841 0.0008927501 
ROBO4 salmon 0.3692898791 0.0013034533 
TPM2 salmon 0.2905587814 0.012640462 
IGFN1 salmon 0.075871542 0.523487547 
SAMD9 salmon 0.0696433036 0.5582289863 
PHC3 tan -0.248536845 0.033985847 
IGBP1 tan 0.1364529693 0.2496804072 
PARK7 tan 0.0981667219 0.408657332 
PLEKHH2 tan -0.0422996931 0.7223423825 
DHX57 turquoise -0.5796680162 7.7117336889953E-008 
DMXL2 turquoise -0.5295977321 1.45162110059404E-006 
DPP8 turquoise -0.4862841059 1.2902939889743E-005 
TENC1 turquoise 0.4583332905 4.54902471252079E-005 
CCDC154 turquoise 0.4319540491 0.000135672 
VPS35 turquoise -0.423585785 0.0001884035 
HS6ST2 turquoise -0.4200393583 0.0002159787 
ZNF223 turquoise -0.4108469883 0.0003056042 
SNCA turquoise -0.3956265127 0.0005314399 
NLGN4X turquoise -0.3704344803 0.0012555251 
PARK2 turquoise -0.3566185123 0.0019557833 
PHKA2 turquoise 0.3093730941 0.0077368411 
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DGKH turquoise -0.2865821522 0.0139676942 
ZNF766 turquoise 0.2787451341 0.0169388229 
SHANK2 turquoise -0.2670018541 0.0223999276 
ATP2B4 turquoise -0.1596029675 0.1774089443 
PITRM1 yellow -0.3229444972 0.005324712 
SPTBN2 yellow -0.2450340863 0.0366712807 
HTT yellow -0.2013999685 0.0875217282 
RTN4R yellow -0.1450726385 0.2207266629 
MSLNL yellow -0.1275507564 0.2822027431 
GRB7 yellow -0.1245424439 0.2938013021 
MAP1A yellow -0.112379664 0.3438411479 
TMEM63C yellow -0.0994998241 0.4022919047 
FCF1 yellow -0.0920893074 0.4384106881 
TTLL12 yellow 0.0655148107 0.5818464394 
PCNT yellow -0.0649449272 0.585142062 
GCKR yellow -0.058020253 0.625847208 
MYO15A yellow -0.0421332638 0.7233908201 
*GS: Gene significance. 
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Project 2: Mitochondrial endo-phenotype of 
Parkinson's disease. 
 
 
 
2.1 Introduction 
 
Mitochondria play a prominent role in energy metabolism and are involved in 
various cellular processes such as cell death pathways, calcium homeostasis and 
stress response pathway (Osellame, Blacker et al. 2012). Mitochondria are a 
source of reactive oxygen species (ROS) and increase in ROS formation activates 
protective stress response pathway. Moreover, impairment of mitochondrial 
function increases oxidative stress, and it promotes aging and 
neurodegeneration (Fukae, Mizuno et al. 2007). In 1990s, Schapira et al. studied 
the structure and function of mitochondrial respiratory-chain enzyme proteins 
in substantia nigra pars compacta (SNpc) of postmortem samples from 
Parkinson’s disease (PD) patients and controls and observed defects of complex I 
activity in the SNpc of these individuals (Schapira, Cooper et al. 1989). Hence, 
mitochondrial dysfunction plays a role in the pathogenesis of PD. However, 
mitochondrial dysfunction is a primary cause of disease in a small group of 
patients with PARK2 and PINK1 mutations in a family with an autosomal 
recessive mode of inheritance. Mitophagy, i.e. elimination of damaged 
mitochondria is disrupted due to loss of function mutation in these genes 
(Rakovic, Shurkewitsch et al. 2013). Parkin, which is encoded by PARK2, 
prevents mitochondrial swelling, cytochrome c release and caspase activation 
but Parkin mutations and proteasome inhibitor abrogate its protective effect 
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(Muftuoglu, Elibol et al. 2004, Palacino, Sagi et al. 2004). Moreover, the 
protective function of Parkin is also affected by S-nitrosylation, which impairs its 
ubiquitin-ligase activity (Clark, Dodson et al. 2006). PINK1 deficiency results in 
loss of SNpc dopamine neurons, abnormal mitochondrial morphology, inhibition 
of complex I activity and ultimately increase in oxidative stress (Kitada, Pisani et 
al. 2007, Gautier, Kitada et al. 2008, Blesa, Trigo-Damas et al. 2015). Some 
studies have shown a decrease in complex I (i.e. NADH ubiquinone 
oxidoreductase) activity in patients with idiopathic PD (Parker, Boyson et al. 
1989).  
 To understand whether a mitochondrial genetic subtype of PD could be 
identified from a large cohort of sporadic patients, all genes laying under the 
meta-analyses of PD Genome-Wide Association Studies (GWAS) (Nalls, Pankratz 
et al. 2014) were annotated with Gene Ontology, MitoCarta (Calvo, Clauser et al. 
2016) and the Integrated Mitochondrial Protein Index databases. A total of 15 
genes with a mitochondrial annotation were selected from the 24 PD risk loci 
(Nalls, Bras et al. 2015). These 15 genes were tagged with 8 Single Nucleotide 
Polymorphisms (SNPs) that were utilized to perform a series of risk profiling 
analyses in a large German cohort of 1,283 PD cases and 876 controls from 
exome genotyping array. On the basis of these risk scores, individuals were 
selected to undergo a series of clinical trials along with patients carrying 
mutations in Mendelian PD genes such as PARK2 and PINK1. Results from these 
analyses will help to understand whether individuals with a high load of 
mitochondrial risk variants are comparable to those with causative mutations in 
nuclear mitochondrial genes. 
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 The function of a gene is most likely affected by rare variants in protein 
coding regions, so we investigated the burden of rare variants in mitochondrial-
related genes in sporadic PD cases compared to controls. The association tests 
were performed using a large repository of WES data from International 
Parkinson’s disease Genomics Consortium (IPDGC). The results were further 
replicated using a genotyping array data (Nalls, Bras et al. 2015). 
 
2.2 Methods 
 
2.2.1 Selection of genes under PD GWAS peaks: 
 
All significant 24 loci were selected from the PD GWAS published in 2014 (Nalls, 
Bras et al. 2015). PLINK (Chang, Chow et al. 2015) was used to identify all 
tagSNPs in strong linkage disequilibrium (LD) (r2≥0.8) with the reported risk 
SNP, within a 1Mb window using data from the European population in 1000 
genomes (http://www.internationalgenome.org/). Haplotype blocks were 
estimated by the default procedure implicated in PLINK by Gabriel et al., which 
defines it as regions with a low historical combination. Such haplotype blocks 
were determined for the most distant tagSNPs on both sides of the sentinel SNP 
(Gabriel, Schaffner et al. 2002). As low-frequency variants in coding regions are 
more likely to be functionally important, all coding regions within a 1Mb window 
surrounding each GWAS top-hit are included as targets, irrespective of estimated 
LD patterns. 
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2.2.2 Selection of Mitochondria-related genes: 
 
We were interested only in genes with mitochondrial involvement, so we 
selected genes from MitoMiner (Smith, Blackshaw et al. 2012), which is a 
resource of mitochondrial localization evidence. It comprises of Gene Ontology, 
MitoCarta (Calvo, Clauser et al. 2016) and Integrated Mitochondrial Protein 
Index (IMPI) databases. MitoCarta comprises of 1,158 human and mouse genes 
encoding proteins with a strong support of mitochondrial localization (Calvo, 
Clauser et al. 2016). IMPI contains 1,550 human genes that encode 
mitochondrially localized proteins, out of which 1,130 are known to be 
mitochondrial, and 420 are predicted to be mitochondrial using the evidence in 
MitoMiner. Hence, we annotated the genes covered by the 24 risk loci in the PD 
GWAS (Nalls, Pankratz et al. 2014) using these three databases and selected the 
genes with mitochondrial annotation. The associated SNPs (Nalls, Pankratz et al. 
2014) tagging these genes were further used for risk profiling. 
 
2.2.3 Risk profiling study:  
 
NeuroX consists of approximately 240,000 exonic variants standard to the 
Illumina Human Exome array, and 24,000 variants were focused on 
neurodegenerative diseases (Nalls, Bras et al. 2015). German population data 
from exome genotyping array NeuroX, comprising 1,283 PD cases and 876 
controls were used for risk profiling. The associated SNPs from the meta-analysis 
of 2014 (Nalls, Pankratz et al. 2014) containing genes involved in mitochondrial 
function were extracted from this cohort. In order to estimate the cumulative 
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genetic risk per individual, allelic scoring was performed using PLINK1.9 (Chang, 
Chow et al. 2015). The allelic score is merely a sum of the number of effect alleles 
at each SNP multiplied by the natural logarithm (ln) of ODDs ratio (OR) for that 
SNP (Chang, Chow et al. 2015). The effect allele and the OR for the selected list of 
SNPs in the German population were retrieved from PDGENE 
(http://www.pdgene.org/). Moreover, by default, copies of unnamed allele 
contribute zero to score, while missing genotypes contribute an amount 
proportional to the imputed allele frequency (Chang, Chow et al. 2015). Age at 
onset (AAO) is also crucial along with the risk of the disease. AAO of PD has high 
heritability and has been reported to be associated with some of the common 
variants (Cai, Alp et al. 2002).To estimate a correlation between the age at onset 
(AAO) of PD and the determined risk scores, Pearson correlation coefficient and 
its significance were calculated using R. 
 
2.2.4 Association analysis:  
 
We performed association tests between a set of rare variants and dichotomous 
phenotypes. For the rare variants (MAF<0.01), gene-based optimal sequence 
kernel association test (SKAT-O) were performed. SKAT-O is a combined test, 
which selects significant result by comparing the one-sided model of burden test 
(all variants have the same direction of effect) and two-sided model of SKAT test 
(all variants have a distinct direction of effect) (Lee, Emond et al. 2012). It 
computes gene-level p-values by correcting population stratification with the 
inclusion of 20 multi-dimensional scaling components as covariates. 
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 The following four criteria were used to see the enrichment of rare 
variants: 
• all the rare variants. 
•  Functional variants (frameshift, non-frameshift, start-loss, stop-loss, 
stop-gain, splicing, missense, exonic, 5-prime untranslated regions 
(UTR5), 3-prime untranslated region (UTR3), upstream (-100bp), 
downstream (+100bp) and non-coding RNA (ncRNA)). 
• Coding variants (frameshift, non-frameshift, start-loss, stop-loss, stop-
gain, splicing and missense). 
• Loss of function variants (frameshift, start-loss, stop-gain and splicing). 
 SKAT-O tests were performed using two independent datasets and is 
mentioned in sections 2.2.4.1 and 2.2.4.2. 
 
2.2.4.1 IPDGC exomes:  
 
The discovery cohort WES data consists of 1,450 PD cases and 535 controls from 
the IPDGC consortium, and 1,732 controls from the Rotterdam study (RSX1) 
WES data. Paired-end sequencing using Illumina HiSeq 2000 was performed for 
IPDGC and RSX1 data. The sequencing reads were aligned to the human 
reference genome (hg19) using BWA-MEM algorithm (Chang, Nguyen et al. 
2010). Binary Alignment Map (BAM) files were generated using Picard tools 
(http://broadinstitute.github.io/picard). Further, variants and small 
insertions/deletions were called using Genome Analysis Toolkit (GATK) 
(McKenna, Hanna et al. 2010). The IPDGC and RSX1 datasets were merged by the 
joint variant calling of the g.VCF files. Genotype and variant quality control was 
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performed using KGGSeq (Cingolani, Platts et al. 2012) and is already mentioned 
in detail in the previous chapter. It was followed by individual quality controls by 
excluding samples with gender inconsistencies, heterozygosity outliers, 
duplicate samples, individuals of divergent ancestry and missing genotype. After 
QC, the IPDGC-RSX1 dataset comprises of 545,752 SNPs and 70,548 indels. The 
sequence-kernel association test (SKAT-O) was performed using EPACTS tool 
(https://genome.sph.umich.edu/wiki/EPACTS) to estimate the burden of rare 
variants in mitochondria-related genes. 
 
2.2.4.2 NeuroX: 
 
Data from 6,801 PD cases and 5,970 controls genotyped with the NeuroX array 
was used for replication. The QC of this data was performed by excluding 
variants with a minimum call rate less than 85%, a Hardy Weinberg Equilibrium 
(HWE) p-value less than 1E-06 in all the controls, or when the missingness rate 
was significantly different between cases and controls. Individuals with sex 
discordance, a heterozygosity rate of >3 standard deviations from the mean, 
more than 15% of missing genotypes, closely related to another individual in the 
dataset (>18.5%) or representing a population outlier after multi-dimensional 
scaling analysis were removed from further analyses. After QC, gene-based 
SKAT-O test was performed using EPACTS tool, same as in discovery cohort.  
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2.3 Results 
2.3.1 Selection of genes under the PD GWAS peaks 
The 24 PD risk loci from GWAS of 2014 consists of 697 genes, which were 
selected based on all the SNPs in LD to the associated SNP as well as all the genes 
under the haplotype block. 
 
2.3.2 Selection of mitochondria-related genes 
 
A total of 933 genes are annotated with a mitochondrial function, biological 
process or cellular component in all three databases utilized. Out of the 697 
genes covered by the 24 risk loci, only 15 genes have the mitochondrial 
annotation. These 15 genes are tagged by 8 common SNPs associated with PD 
(table12). 
 
2.3.3 Risk Profiling 
 
The purpose of these analyses was to select all the associated variants with 
mitochondrial annotation from the sporadic PD data and perform risk profiling 
in the German population. The main aim of risk profiling was to stratify the 
patients in mito+ and mito- category. The mito+ group consists of all the patients 
with high risk and the mito- group with low risk to PD on the basis of 
mitochondrial phenotype. Results of the risk profile performed for the German 
population are shown in figure 9. Higher positive scores indicate a higher risk of 
developing PD due to mitochondrial phenotype. In the German population, high 
 82 
allelic scores (score>0.35) are significantly more present in PD cases than in 
controls, while the low scores (score<-0.35) are over-represented in controls 
(table 13).  
 AAO of the disease might be genetically influenced and may have a similar 
effect to most of the risk genes. In our study, it was observed that AAO of all PD 
cases from Germany is significantly correlated to the risk scores (figure 10) 
(table 3). Several lines of evidence have shown mitochondrial impairment in PD 
patients due to PARK2 and PINK1 mutations (Clark, Dodson et al. 2006, Zanellati, 
Monti et al. 2015). Some of the German PD cases with allelic scores higher than 
0.35 (mito+) or less than -0.35 (mito-) as well as PD patients carrying 
PARK2/PINK1 mutations, will undergo clinical trials with coenzyme Q10 and 
vitamin K2. Coenzyme Q10 is an antioxidant and plays a vital role in 
mitochondrial electron transport pathway (Duberley, Heales et al. 2014). 
 
Table 12: 8 associated SNPs whose locus has genes with mitochondrial annotation. 
 
Associated 
SNP 
Locus name Effect allele MAF (1000 
Genomes, 2016) 
OR (Germany) 
 
rs329648 MIR4697 
 
T 0.46 1.15 
 
rs34311866 TMEM175-GAK-DGKQ 
 
G 0.14 1.40 
 
rs11868035 SREBF1-RAI1 
 
A 0.49 0.97 
 
rs14235 BCKDK-STX1B 
 
A 0.36 1.19 
 
rs11060180 CCDC62 
 
G 0.25 0.90 
 
rs71628662 GBA-SYT11 
 
T 0.01 0.40 
 
rs199347 GPNMB 
 
C 0.48 0.97 
 
rs12637471 MCCC1 
 
A 0.34 0.67 
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Figure 9: Density plot of the allelic scores calculated for German population: PD cases with 
score >0.35 represents the mito+ group, while cases with score <-0.35 represents the 
mito- group. 
 
 
 
 
Table 13: Risk profiling of 8 GWAS associated SNPs in German population: 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Correlation of risk scores and age at onset for all cases: AAO of all the German 
PD cases are significantly correlated to risk scores of the associated SNPs 
 
. 
 
 
 
Allelic scores German_Cases German_Controls Chi.sq test (P.value) 
>0.35 240 104 
0.0003303 
 
<-0.35 
 
152 
 
197 3.747e-08 
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Table 14: Correlation between allelic scores and age at onset of German PD cases 
 
Correlation coefficient Test statistic P-value 
-0.051 
 
-2.18 
 
0.02 
 
 
2.3.4 Association analysis 
2.3.4.1 IPDGC exomes: 
 
The WES data from IPDGC consists of 840 mitochondria-related genes. The 
results of the gene-based SKAT-O analysis using the IPDGC discovery cohort for 
the mitochondria-related rare variants are presented in table 15. We used four 
different criteria to see the enrichment of rare variants. The first criteria show 
the burden of all rare variants (MAF<0.01) in the respective genes, secondly to 
see enrichment of functional variants and followed by coding and loss of function 
variants. In these gene-based analyses besides the expected association of GBA 
(P=4.2109E-006) to PD risk, we also identified an association of all rare and 
functional variants in CS, MTHFD1L, FAM162A, POLRMT, AK4, MRPS11 and 
ALDH1L1 to PD. Moreover, rare coding variants in COX19, and loss of function 
variants in CISD2, HK2 and ATPAF1 are highly enriched to PD. 
 
Table 15: Gene-based SKAT-O results for IPDGC exomes. 
 
Gene Nallrare Pallrare Pfunctional Pcoding Plof 
CS 31 1.706E-015 1.8029E-015 1.8029E-015 0.042088 
FAM162A 1 0.000000045 0.000000045 0.000000045 0.000000045 
MTHFD1L 67 7.9283E-008 2.6699E-006 0.000002693 0.000028237 
POLRMT 75 1.0953E-007 8.9496E-008 8.9496E-008 0.73951 
AK4 21 1.1047E-007 0.34662 0.33658 0.13605 
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GBA 67 4.2109E-006 0.000003508 1.7849E-006 0.058283 
MRPS11 19 0.000015624 0.000045796 0.0016708 NA 
ALDH1L1 159 0.000027259 0.071281 0.032693 0.88537 
COX19 5 0.12036 0.062512 0.000012906 NA 
CISD2 6 0.0724 0.13855 0.13855 2.2401E-012 
HK2 68 0.20689 0.76275 0.75506 2.1593E-010 
ATPAF1 32 1 0.91219 0.91219 0.000026057 
* Nallrare: Number of all rare variants; Pallrare: P-value for all rare variants; Pfunctional: P-value for functional 
variants; Pcoding: P-value for coding variants; Plof: P-value for loss of function variants. 
 
 
 
2.3.4.2 NeuroX: 
 
The genotyping array NeuroX covers 814 mitochondria-related genes. This data 
was used to replicate the findings from discovery cohort SKAT-O analysis. This 
data consists of 6,801 PD cases and 5,970 controls of European ancestry. As 
already mentioned in the previous section, for this dataset as well, we used 4 
criteria to see the enrichment of rare variants. The results of the gene-based 
SKAT-O results for NeuroX are mentioned in table 16. In the replication cohort, 
only GBA is replicated.  In this cohort, Mendelian PD gene LRRK2 and a novel 
gene CHCHD6 shows genome-wide association to PD. 
 
Table 16: Gene-based SKAT-O results for NeuroX. 
 
Gene Nallrare Pallrare Pfunctional Pcoding Plof 
CHCHD6 9 5.1486E-041 5.1486E-041 5.1486E-041 0.33024 
LRRK2 116 5.6104E-009 5.9088E-009 5.9088E-009 0.70593 
GBA 13 3.1964E-006 2.1615E-006 2.1615E-006 NA 
CS 1 0.42 0.42 0.42 NA 
FAM162A 7 0.58 0.58 0.58 0.44 
MTHFD1L 17 0.47 1 1 NA 
POLRMT 6 0.14 0.14 0.14 NA 
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AK4 1 NA NA NA NA 
MRPS11 2 0.83 0.83 0.83 NA 
ALDH1L1 27 1 1 1 0.53 
COX19 2 0.41 0.41 0.41 NA 
CISD2      
HK2 7 0.63 0.44 0.44 NA 
ATPAF1 1 0.06 0.06 0.06 NA 
* Nallrare: Number of all rare variants; Pallrare: P-value for all rare variants; Pfunctional: P-value for functional 
variants; Pcoding: P-value for coding variants; Plof: P-value for loss of function variants. 
 
 
2.4 Discussion 
 
Parkinson’s disease is quite heterogeneous concerning genetic, environmental 
and clinical point of view, so there is a need for defining subtypes of PD that 
allows assigning therapeutic approaches. Genetic evidence and biochemical 
studies indicate that mitochondrial dysfunction, ensuing cellular energy failure 
and oxidative stress may be one of these crucial disease pathways in a subgroup 
of PD patients (Reeve, Grady et al. 2018). So, the important question in this study 
was to identify the sub-group, i.e. the mitochondrial endo-phenotype of PD using 
existing genomic data. We hypothesized that if an individual’s allelic score 
represents an overall load of PD risk alleles, then an individual’s disease liability 
should be somehow related to their allelic score. AAO of PD has high heritability, 
so we also investigated the relationship between age at onset and allelic scores. 
The cumulative genetic risk per individual in the German population was 
estimated using the 8 GWAS associated SNPs tagging genes with mitochondrial 
annotation. Our analysis shows that 240 PD cases and 104 controls have an 
allelic score greater than 0.35 and these cases were stratified as mito+ group. 
Moreover, 152 cases and 197 controls have allelic scores less than -0.35, and 
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these cases were stratified as mito- group. Hence, positive allelic scores were 
significantly present in more cases than in controls, while the negative scores 
were over-represented in controls. The age at onset of all German cases was 
significantly correlated to the risk scores. Some of the patients from these mito+ 
and mito- subgroups as well as PD patients with PARK2 and PINK1 mutations 
will undergo clinical trials with coenzyme Q10 and vitamin K2, in order to 
improve complex I activity. The application of drugs targeting complex I function 
has already been mentioned (Marella, Seo et al. 2009). Coenzyme Q10 is an anti-
oxidant, and it influences mitochondrial activity including complex I (Zhu, Sun et 
al. 2017).      
 As rare variants in a coding region most likely affect the function of the 
gene, so we determined the burden of rare variants in nuclear mitochondrial 
genes. We investigated a large repository of WES data and identified that beside 
GBA some other genes such as CS, MTHFD1L, FAM162A, POLRMT, AK4, CISD2, and 
HK2 also showed genome-wide association to PD. The protein encoded by the 
gene Citrate Synthase (CS) is a rate-limiting enzyme of Krebs tricarboxylic acid 
cycle and plays a role in regulating energy generation of mitochondrial 
respiration. Abnormal trafficking of CS isoform-a plays a role in mitochondrial 
dysfunction (Cheng, Liao et al. 2009). MTHFD1L, which encodes the 
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like protein) 
influences homocysteine-related pathways as it plays a role in the generation of 
methionine from homocysteine and has been associated with late-onset 
Alzheimer’s disease (AD) (Naj, Beecham et al. 2010). Moreover, high plasma 
homocysteine levels have been implicated in neurodegenerative diseases like AD 
and PD (Herrmann and Knapp 2002). As per experimental evidence of Affinity 
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Capture-Mass spectrometry MTHFD1L interacts with NDUFS6 (NADH: 
Ubiquinone Oxidoreductase Subunit S6), i.e. Complex I. Diseases associated with 
NDUFS6 includes Mitochondrial Complex I deficiency and Leigh syndrome 
(Kirby, Salemi et al. 2004). Several lines of evidence have suggested that 
impairment of complex I contribute to PD pathogenesis (Schapira, Cooper et al. 
1990). FAM162A is involved in positive regulation of apoptotic process and 
hypoxia-induced cell death of neuronal process (Lee, Kim et al. 2004). POLRMT 
encodes a mitochondrial RNA polymerase and is responsible for mitochondrial 
gene expression. The protein encoded by CISD2 is a zinc finger protein and may 
play a role in calcium homeostasis. It also contributes to antagonizing BECN1-
mediated cellular autophagy in the endoplasmic reticulum (Chang, Nguyen et al. 
2010). 
 We further replicated our findings in genotyping array and observed that 
only GBA from the discovery cohort is significantly associated with PD. 
Moreover, rare variants in PD Mendelian gene LRRK2 and a novel gene CHCHD6 
show genome-wide association to PD. The novel gene CHCHD6 is involved in 
biological processes such as cristae formation and cellular response to DNA 
damage stimulus. It is involved in regulation of mitochondrial cristae 
morphology, cell growth and ATP production. The mitochondrial functions are 
dependent on the structural integrity of mitochondrial cristae (An, Shi et al. 
2012). Our current study results implicate new PD associated genes apart from 
the known PD causal genes such as LRRK2 and GBA. Two frequent LRRK2 
mutations p. G2019S and p. R1441C increases mitochondrial autophagy and 
accumulation of autophagic vacuoles, resulting in degeneration of dopaminergic 
neurons (Esteves and Cardoso 2016). The published report shows that in a cell 
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culture model inhibition of GBA causes impairment in mitochondrial function 
(Cleeter, Chau et al. 2013). Lack of replication could be due to differences in age 
of disease onset and the laboratory techniques applied to both WES and NeuroX 
data. Since the NeuroX data was restricted to variants included in the genotyping 
array, it could be possible that many pathogenic variants were missed. Further 
investigation on the functional level might improve our understanding of these 
candidate genes associated with PD.  
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Project 3: Transcriptomic analysis of genes under 
the PD GWAS loci. 
 
 
3.1 Introduction 
 
Genome-wide association studies (GWAS) helps to estimate an association of 
single nucleotide polymorphisms (SNPs) and trait. It helps to perform a 
statistical comparison of allele frequencies between cases and controls and has 
the power to study the genetic basis of disease by assaying the entire genome 
(Visscher, Wray et al. 2017). GWAS have identified many common genetic 
variants associated with PD. Early GWAS has produced inconsistent results due 
to small sample size (Evangelou, Maraganore et al. 2007) but recent GWAS meta-
analysis has identified loci such as LRRK2, SNCA, GAK, BST1 and PARK16, which 
were confirmed in the independent follow-up studies (Pankratz, Wilk et al. 2009, 
Satake, Nakabayashi et al. 2009, Simon-Sanchez, Schulte et al. 2009). In 2014, a 
large meta-analysis of GWAS identified 24 risk loci for PD (Nalls, Bras et al. 
2015). Recently, a large meta GWAS identified 17 new loci for PD, so now 41 loci 
have been associated with Parkinson’s disease risk in individuals of European 
ancestry (Chang, Nalls et al. 2017). Additionally, GWAS of PD in East Asians 
showed strong association signal at SNCA, LRRK2 and MCCC1, which confirms a 
role of these loci in European and Asian PD (Foo, Tan et al. 2017). 
mRNA sequencing is an accurate and highly sensitive means to quantify gene 
expression. It gives complete information of the coding transcriptome and can 
identify known and novel transcript isoforms and gene fusions. Assessment of 
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gene function by silencing gene expression using plasmids has been facilitated by 
RNA interference (RNAi) (Check 2007). Availability of short hairpin RNA 
(shRNA) libraries has made it possible to relate genes or cluster of genes to a 
normal or pathological biological process using gene expression analysis. Our 
interest in the study was to elucidate the genes responsible for PD risk at the loci 
implicated by the latest PD GWAS. Genes under the associated PD loci were 
silenced by shRNA and gene expression was quantified using mRNA sequencing. 
We assessed mRNA levels differences between the knockdown samples and 
scrambles (controls). Furthermore, we also investigated the over-represented 
gene ontology and pathways in differentially expressed genes. 
 GWAS approaches helps to identify common risk variants, while the 
missing heritability can be explained by rare variants. The function of a gene is 
most likely affected by rare variants in protein-coding regions. Hence, we 
investigated the genetic burden of rare variants in the genes under PD GWAS loci 
using exome-sequenced data generated for PD risk loci from a meta-analysis of 
2011 (International Parkinson Disease Genomics, Nalls et al. 2011). 
3.2 Methodology 
3.2.1 Selection of genes under the GWAS loci: 
 
All significantly associated loci from GWAS on PD were selected (Nalls, Pankratz 
et al. 2014, Chang, Nalls et al. 2017). PLINK was used to identify all tagSNPs at 
r2≥0.8 with the reported GWAS hit, within a 1Mb window using data from the 
European population in 1000 genomes. Haplotype blocks were estimated by the 
default procedure implicated in PLINK for the most distant tagSNPs on both 
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sides of the GWAS SNP (Gabriel, Schaffner et al. 2002). As low-frequency variants 
in coding regions are more likely to be functionally important, all coding regions 
within a 1Mb window surrounding each GWAS top-hit are included as targets, 
irrespective of estimated LD patterns (Purcell, Neale et al. 2007). 
3.2.2 Knockdown of genes: 
 
Genes such as ATP13A2, RGS10, TIAL1, MCMBP, SEC23IP, INPP5F, BAG3, BST1, 
CCDC62, COASY, DLG2, FDFT1, ITGA8, MAP4K4, MCCC1, NUCKS1, RAB29, GCH1, 
WDHD1, DALRD3, ARIH2, IMPDH2, P4HTM, PRKAR2A, QARS, QRICH1, USP19, 
WDR6, PRSS8, VKORC1, KAT8, STX4, ZNF668, BIN3, PDLIM2, ELOVL7, ERCC8, 
SIPA1L2, SREBF1, SYT17, TMEM175, DGKQ, GAK and ZFYVE26 were successfully 
knockdown with at least 50% efficiency by introducing shRNA into human 
dopaminergic BE(2)-M17 neuroblastoma cell lines through infection with virus. 
The scrambled controls were replicates of the same treatment. The goal was to 
mimic the effects of the viral transduction without the shRNA having any effect. 
Thus, the scrambled control is a vector, which does not target any gene. The 
sequence of the shRNA has been scrambled. Since the viral transduction also 
affects gene expression, this is a much better control than cells which have not 
been transduced. 
3.2.3 Transcriptomic analysis: 
 
mRNA sequencing: RNA was isolated on EpMotion using a Promega 96 well kit. 
cDNA of normalized RNA has been synthesized using Mantis 
(https://formulatrix.com/liquid-handling-systems/mantis-liquid-handler/). 
Sequencing was performed at CeGat (https://www.cegat.de/). Samples were 
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sequenced on a SR Flowcell with 1*50bp and Dual-Index on the Illumina 
HiSeq4000. 
 Preliminary quality control or pre-processing of the reads was done using 
Trimmomatic (Bolger, Lohse et al. 2014). It performs sliding window trimming. 
Cutting is done once the average quality within the window of 4 bases falls below 
20. Bases with a quality score less than 20 from the beginning and end of the 
read were removed. Reads were dropped if a length is less than 50bp. Quality 
control reports were generated using FASTQC 
(https://www.bioinformatics.babraham.ac.uk/projects/fastqc). Reads were 
mapped against the human reference genome (build hg38) using HISAT2 (Kim, 
Langmead et al. 2015). This mapping information was used to quantify reads 
further. HISAT uses two types of indexes for alignment, whole-genome index and 
tens of thousands of small local indexes. Both types of the index are constructed 
using the Burrows-Wheeler transform (BWT)/Ferragina-Manzini(FM) index 
(Kim, Langmead et al. 2015). Gene expression quantification was performed 
using featureCounts (Liao, Smyth et al. 2014). This program assign reads to 
features by implementing chromosome hashing and feature blocking. Exons 
were defined to be features and genes as meta-features and quantification was 
done at meta-feature level. As this is mRNA-seq data, reads that overlapped 
multiple genes were excluded from the counts (Liao, Smyth et al. 2014). Gene 
annotation was done using hg38 Ensembl GTF (General Transfer Format) file 
(https://www.ensembl.org). Normalization between samples was performed 
using relative log expression (RLE) method. All the genes with counts per million 
greater than 1 in at least 50% of the KD cell lines and 20% of the control samples 
were retrieved. Furthermore, the estimation of the mRNA level difference 
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between the knockdown samples of each gene and scrambles (controls) was 
performed. All these steps of normalization, filtering and log fold change (logFC) 
calculation have been performed using EdgeR (Robinson, McCarthy et al. 2010). 
 
Gene-set Enrichment: 
 
Gene set over-representation has been performed using HTSAnalyzeR package in 
R (Wang, Terfve et al. 2011). Over-representation analysis is performed based on 
the hypergeometric test (Subramanian, Tamayo et al. 2005). It is followed by a 
superexact test to compute statistical distributions of multi-set intersections. 
This R package helps to intersect over-represented biological processes (BP) and 
pathways from all knockdown genes under the associated loci as well as 
Mendelian PD genes (PARK7, PINK1 and VPS35) knockdown cell lines. This 
approach helps to know which over-represented biological processes and 
pathways are overlapped on silencing PD causal genes and genes under the 
associated loci of PD.  
 
3.2.4 Association analysis: 
 
We used NGS data generated for the 11 PD risk loci such as MAPT, SNCA, HLA-
DRB5, BST1, GAK, LRRK2, ACMSD, STK39, MCCC1/LAMP3, SYT11, and 
CCDC62/HIP1R as per the meta-analysis of 2011 (International Parkinson 
Disease Genomics, Nalls et al. 2011). In the IPDGC resequencing project, there 
are total 4,514 samples. A total of 3,060 patients diagnosed with Parkinson's 
disease and 1,454 controls were included in the study. KGGSeq (Cingolani, Platts 
et al. 2012) was used to apply quality control (QC) filters on individual genotypes 
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and genomic variants. In brief, genotypes with a Phred quality score below 20, a 
read depth of less than 10, the second smallest normalized Phred-scaled 
genotype likelihood below 20 were removed. A minimum overall sequencing 
Phred quality score below 50, an overall mapping quality Phred score below 20, 
an overall strand bias Phred-scaled p-value (using Fisher's exact test) above 6 
were considered. Variants within putative super-duplicate genomic regions were 
excluded. Only sites with Minor Allele Count greater than or equal to 1 were 
included. Sites with more than 5% missing data and markers with different 
genotype call rate between cases and controls (P<5.0E-8) were excluded. Related 
individuals, as well as individuals with genotype failure rate greater than 5% and 
heterozygosity rate >3 standard deviations from the mean, were excluded. 
Individuals with more than 5% missing genotype and divergent ancestry were 
removed.  
After performing quality control 74,497 rare variants (MAF < 0.01) were 
retrieved. The sequence-kernel association test (SKAT-O) was performed using 
EPACTS tool to estimate the burden of rare variants in genes under PD GWAS 
loci between PD cases and controls. 
 
3.3 Results 
 
3.3.1 Transcriptomic analysis 
 
The mRNA sequencing was performed after efficiently silencing 44 genes under 
the PD GWAS loci. About 78% of the reads were mapped to the human reference 
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genome. The mRNA levels differences between the knockdown samples and 
scrambles (controls) in terms of logFC are listed in table 17. -synuclein is 
genetically and neuropathologically linked to PD and also contributes to its 
pathogenesis (Mezey, Dehejia et al. 1998), Moreover, several lines of evidence 
have shown that increase of SNCA dosage (duplications and triplications) cause 
familial PD (Chartier-Harlin, Kachergus et al. , Singleton, Farrer et al. 2003). 
Hence, we investigated SNCA mRNA levels in knockdown cell lines compared to 
controls. -synuclein was upregulated in COASY, ITGA8 and P4HTM KD cell lines 
and downregulated in BAG3, GCH1, WDHD1, GAK and QRICH1 KD cell lines (figure 
11). Over-represented biological processes and pathways for the differentially 
expressed genes between the knockdown samples and controls are listed in 
table 19. We prioritized the knockdown genes on the basis of differentially 
regulated -synuclein mRNA levels. The enriched biological processes in all such 
prioritized knockdown genes are signaling pathways such as integrin-mediated 
signaling pathway, G-protein coupled receptor signaling pathway, cytokine-
mediated signaling pathway, chemical synaptic transmission, inflammatory 
response, potassium ion transport, microtubule-based movement, positive 
regulation of synapse assembly and activation of protein kinase activity. 
Moreover, ECM-receptor interaction, Cardiomyopathy related pathways, Calcium 
Signaling pathway and Cytokine-cytokine receptor interaction are over-
represented in the differentially regulated genes of the knockdown samples. 
Mendelian PD genes such as PINK1, PARK7 and VPS35 were also knockdown in 
the neuroblastoma cell lines. Targeted genes such as ITGA8, DLG2, GCH1 and 
PRSS8 were upregulated on silencing PINK1 expression by shRNA. However, in 
PARK7 knockdown samples compared to scrambles, it was observed that ITGA8, 
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DLG2, SIPA1L2 and PRSS8 were upregulated. Biological processes namely 
inflammatory response and G-protein coupled receptor-signaling pathway, and 
KEGG pathways such as Cytokine-cytokine receptor interaction and Systemic 
lupus erythematosus were over-represented in the differentially regulated genes 
of the knockdown samples PARK7, VPS35 and PLA2G6 compared to controls. 
 
 
 
 
Table 17:  logFC for PD causal genes in all knockdown samples. 
Loci KD_gene KD_gene_logFC LRRK2 PRKN SNCA PARK7 UCHL1 VPS35 VPS13C PINK1 
ATP13A2 ATP13A2 -3.4001489986 1.1213126192 
-
1.7332130356 
-
0.3762245145 
-
0.1885204575 
-
0.1801326195 
0.0166611073 0.2400252982 
-
0.2386525382 
BAG3 RGS10 -5.6839915855 0.1732731149 1.6048883787 
-
0.1446958878 
-0.352208502 0.1051298671 0.0970311092 0.2924230163 1.2590587143 
BAG3 TIAL1 -2.2725924059 
-
0.2004797731 
1.1765423192 
-
0.0700936341 
0.12323508 0.2011502427 
-
0.2010760343 
0.1222476365 
-
0.5453874303 
BAG3 MCMBP -1.248804293 
-
0.1739839149 
0.8686284941 
-
0.6633991485 
-
0.0305408472 
-
0.6352692575 
-
0.2086198415 
0.582794857 -0.28659651 
BAG3 SEC23IP -1.749333671 -1.201417986 0.3629724111 
-
0.0370451061 
-
0.0981230816 
-
0.6095311137 
0.0934845418 
-
0.4303787973 
0.7767960256 
BAG3 INPP5F -1.562700554 1.2341259078 0.7697803294 0.2214197322 0.0067806853 0.0289317621 -0.320137424 0.2344492987 0.3477868803 
BAG3 BAG3 -4.8520647604 
-
1.1389867618 
2.7831876465 
-
2.0385274195 
0.168619571 0.3508633254 
-
0.2154392144 
0.7184181391 
-
0.5469920256 
BST1 BST1 -5.4846570989 
-
0.0724520332 
1.8726145056 
-
0.4571225779 
-
0.4201967678 
0.1210338826 0.2251208694 0.1570401938 0.0207945147 
CCDC62 CCDC62 -0.5529912921 
-
2.5743434995 
-
0.1927281824 
0.026926012 0.0191856597 0.2441198597 
-
0.2118674274 
0.0721776804 0.2063032723 
COASY COASY -1.6016872511 
-
4.4579391869 
0.4467583692 1.134467799 
-
0.3318350301 
0.3694866527 
-
0.7385709039 
0.9746855374 
-
0.1401101933 
DLG2 DLG2 0.0839970286 0.9165742122 -0.147092634 1.8265965726 0.012151361 0.0503391647 0.2239031596 0.2427578617 0.6727340019 
FDFT1 FDFT1 -1.8632102833 
-
0.5307521307 
-
0.4392129434 
-
0.3593633873 
-
0.0391818494 
-
0.0631387459 
-
0.2734277378 
0.3317302549 0.1156346214 
ITGA8 ITGA8 -5.154171029 
-
0.1707847161 
0.3385726536 1.0242087623 
-
0.3432235444 
-0.165475612 
-
0.0126993222 
0.0613794474 
-
0.2049559398 
MAP4K4 MAP4K4 -1.5620081396 0.7169362781 0.494039341 0.4572511753 
-
0.0653823416 
0.0268390591 0.0203986169 0.0004982016 0.6228608735 
MCCC1 MCCC1 -2.1109031623 
-
0.6398163754 
0.4086431361 
-
0.5312585069 
-
0.4360169751 
-
0.4944473035 
0.0963619414 
-
0.1169375276 
0.0459323393 
PARK16 NUCKS1 -2.8851325363 
-
4.4126919891 
0.8657870583 
-
0.4586680954 
0.0486245625 
-
0.6475400512 
-
0.2212506889 
-
0.2154837932 
0.0438140816 
PARK16 RAB29 -2.6066768641 0.7974053689 
-
0.3207021753 
-
0.8411159111 
0.0006156777 
-
0.2571994658 
0.2067113864 0.2222535032 
-
0.2823055881 
rs11158026 GCH1 -2.0241468016 
-
2.1708627558 
0.0122804265 
-
1.0386589238 
-
0.1717354183 
-
0.2024217653 
-
0.1286329549 
-
0.0788226612 
-
0.0534477707 
rs11158026 WDHD1 -1.65012158 
-
0.7992780286 
3.5390600304 
-
1.1374911725 
-
0.1484818341 
-
0.4407589932 
-
0.0279271638 
0.6385843198 
-
0.5195465397 
rs12497850 DALRD3 -4.2737216987 
-
0.4248411989 
1.1976333617 0.392846637 
-
0.1461696674 
-
0.5893079144 
-
0.0720607021 
-
0.4146083087 
-
0.7180167912 
rs12497850 ARIH2 -0.9472754935 0.1341090378 
-
0.7282346718 
-
0.1363021963 
-
0.2269595431 
0.2541038207 
-
0.0777846402 
0.3883354082 0.3872929447 
rs12497850 IMPDH2 -0.0575059397 0.4566352755 1.7395651242 0.369795278 - - - 0.4118546761 0.2787305342 
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0.2624250689 0.2185897592 0.4539276498 
rs12497850 P4HTM -1.0533898178 0.5704631948 
-
1.5322867979 
1.9421932857 
-
0.2344901076 
0.4426121281 0.6866660488 0.1377922117 0.8930181453 
rs12497850 PRKAR2A -3.3264677175 1.8846506413 0.9821846677 -0.558949073 
-
0.3284393951 
-
0.6739589133 
-
0.2750235984 
0.3332589614 0.3798352641 
rs12497850 QARS -0.6252627618 0.3948452451 0.7204573656 1.2825765935 0.2220618859 0.0639812742 0.2599526317 0.9696136776 0.8476093107 
rs12497850 QRICH1 -1.7841169334 
-
0.0684554293 
1.255073418 -1.222228491 
-
0.1913239121 
-
0.0043373183 
-0.023238647 0.7600834048 0.4014726593 
rs12497850 USP19 -2.0478829789 0.809059121 1.5518884182 -0.253263611 
-
0.0880613037 
-0.136909176 0.1101560827 
-
0.2931406288 
0.7424688873 
rs12497850 WDR6 -3.0289406706 2.3059084452 
-
2.2526547227 
0.6178067249 
-
0.3102528229 
0.0831956881 
-
0.0755419741 
0.4477298156 0.2216108138 
rs14235 PRSS8 -0.0465932443 
-
1.3968959368 
-
1.7183627152 
0.348897949 
-
0.1278541174 
0.1474951938 
-
0.1096376857 
0.459681461 0.0074062285 
rs14235 VKORC1 -3.2401052651 1.0944056737 0.7998675142 0.8828306524 
-
0.2072590447 
-
0.4923051147 
0.2757155894 0.4965117583 0.0981011805 
rs14235 KAT8 -1.570074826 
-
1.8311318947 
1.7085060134 -0.949627698 
-
0.0372948504 
0.4483743776 
-
0.0073118299 
0.2734308309 
-
0.8659019725 
rs14235 STX4 -1.7441723824 0.0247153253 2.0258906846 0.0332929111 
-
0.0886878267 
-
0.8474356042 
0.2896624418 -0.138462246 
-
0.0317020811 
rs14235 ZNF668 -0.9382411373 0.0851992202 0.8977235156 0.4798709574 
-
0.2219393293 
-
0.3070905512 
0.081111336 0.5235440906 0.2310726593 
rs2280104 BIN3 -0.7463222907 
-
0.9468858039 
0.8878247517 0.5337013916 
-
0.0223195623 
-
0.5385374473 
-
0.2364508321 
-
0.1698382679 
0.2363334984 
rs2280104 PDLIM2 -1.6263117035 0.3490086397 1.1872906181 0.4759124241 
-
0.2866509346 
-
0.3493364669 
0.1316148729 0.322929798 0.353267631 
rs2694528 ELOVL7 -4.6919684023 1.1748260007 
-
4.3221827298 
0.0621673932 
-
0.1045713641 
-
0.4106390163 
0.1459480366 0.0114206766 0.1052541572 
rs2694528 ERCC8 -3.2783039739 
-
0.5329279711 
-0.959679627 0.5240742184 0.0713227307 
-
0.1083426646 
-
0.5009776863 
0.3066381483 0.3785529317 
SIPA1L2 SIPA1L2 0.1386118429 0.0358088297 0.146917271 
-
0.4402458777 
-
0.8798593814 
0.3442089194 0.4971851515 0.6629449464 0.346633125 
SREBF1 SREBF1 -1.6542147224 
-
2.1911500569 
1.1335302882 
-
0.2883126387 
0.0545415309 0.3931279696 0.2680123783 0.287912313 0.7680107705 
SYT17 SYT17 -2.308686327 0.4448659347 0.1003651719 0.2909696441 
-
0.1404947507 
-0.514233593 0.0317583359 0.1515022683 0.3357771047 
TMEM175 TMEM175 -1.0411630705 
-
4.5197032244 
-
4.3962580173 
-
0.5900674364 
-
0.0056393412 
0.1536694835 0.0996739655 
-
0.8677081514 
0.1767587798 
TMEM175 DGKQ -0.661887731 
-
0.0389941613 
-
0.6100671752 
0.556540442 
-
0.3108220165 
-
0.1410464983 
-
0.0258887466 
-0.060947155 
-
0.0027338225 
TMEM175 GAK -1.2555048424 
-
0.1254781513 
1.1806117938 -1.75303873 0.1427104736 
-
0.8099527943 
-
0.4777903028 
0.1014663699 
-
1.0858164517 
ZFYVE26 ZFYVE26 -0.6312201894 1.413370213 0.5636465923 0.7781344678 
-
0.2411392395 
0.1196892648 0.2967592783 0.3251596076 0.8503687596 
* KD_gene: knockdown gene; KD_genes_logFC: log Fold Change of knockdown gene. 
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Figure 11: SNCA mRNA level differences (logFC) between knockdown cell lines and 
controls. 
 
 
 
 
3.3.2 Association analysis: 
 
The resequencing data from IPDGC comprises of only ~20 genes out of the ~50 
genes, which were knockdown using shRNA. The results of the gene-based SKAT-
O analysis for the rare variants in genes under the PD GWAS loci are presented in 
table 18. We used four criteria to see the enrichment of rare variants. The first 
criteria show the burden of all rare variants in the respective genes, secondly to 
see enrichment of functional variants and followed by coding and loss of function 
variants. In these gene-based analyses we identified an association of coding 
variants in GAK and LRRK2 to PD (see table 18). 
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Table 18: Gene-based SKAT-O analysis for rare variants in knockdown genes. 
Gene Nallrare Pallrare Pfunctional Pcoding Plof 
ATP13A2 56 0.36678 0.44989 0.53617 0.52576 
BST1 608 0.51247 1 0.93091 0.49751 
CCDC62 582 0.51461 0.54879 0.5641 0.46173 
DGKQ 164 0.13441 0.26522 0.35556 0.22424 
GAK 1711 0.34098 0.04545 0.022905 0.27866 
KAT8 60 0.5162 0.60767 0.56946 0.78355 
LRRK2 3309 0.17845 0.04513 0.029037 0.64283 
MCCC1 1285 0.70264 0.62297 0.42299 0.44652 
NUCKS1 687 0.28171 0.24955 0.068329 0.53388 
PARK2 194 0.52878 0.43316 0.13434 0.084546 
PARK7 114 0.35533 0.16721 0.10512 0.45157 
PINK1 97 0.138 0.2203 0.2518 0.4011 
PLA2G6 85 0.2725 0.30189 0.19178 0.34141 
PRSS8 19 0.55601 0.54112 0.81371 NA 
SNCA 2431 0.34682 0.33577 0.45705 0.1228 
SREBF1 43 0.22589 0.44998 0.45611 0.63999 
STX4 33 0.64142 0.42503 0.36977 0.27375 
TMEM175 416 0.45443 0.63806 0.65661 0.35907 
VKORC1 19 0.51004 0.43402 0.55915 NA 
VPS35 72 1 0.45918 0.76235 NA 
ZNF668 63 0.082066 0.073258 0.21373 0.55596 
* Nallrare: Number of all rare variants; Pallrare: P-value for all rare variants; Pfunctional: P-value for functional 
variants; Pcoding: P-value for coding variants; Plof: P-value for loss of function variants. 
 
 
 
 
 
3.4 Discussion 
 
The meta-analysis of PD GWAS has identified 41 risk loci (Chang, Nalls et al. 
2017). It is often difficult to identify specific genes responsible for risk at GWAS 
loci, as the regions showing significant association can span multiple genes and 
the nearby gene to SNP with the strongest P-value is not necessarily the one 
responsible for the association. We investigated the genes under the PD GWAS 
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loci to determine the most plausible gene contributing to PD risk and also to 
investigate their role in PD pathways. Our study offers an insight into the 
transcriptome analysis by silencing genes in neuroblastoma cell lines using short 
hairpin RNAs.  
   In this study, we discuss some of the loci in which the targeted 
genes were successfully silenced with at least 50% efficiency through shRNA. In 
the BAG3 locus, amongst the six genes BAG3, INPP5F, SEC23IP, MCMBP, RGS20 
and TIAL1, which were knockdown, -synuclein mRNA levels were 
downregulated by two folds in BAG3 KD samples. Biological processes such as 
integrin-mediated signaling pathway, chemical synaptic transmission, immune 
response and cell adhesion related processes as well as ECM-receptor 
interaction and Cardiomyopathy related pathways were over-represented in 
BAG3 KD samples. As per published studies, Extra Cellular Matrix (ECM) and 
integrin aberrations are likely to contribute to imbalanced synaptic functions 
(Wu and Reddy 2012). BAG3 seems to be a plausible gene in this locus as it also 
plays a role in regulating SNCA clearance via macroautophagy (Cao, Yang et al. 
2017). Experimental evidence of Affinity Capture-Luminescence in the BioGRID 
database (https://thebiogrid.org/) shows that BAG3 interacts with PLA2G6 
(Chen, Yang et al. 2013). Published reports have suggested that a mutation in the 
PLA2G6 gene causes early onset neurodegeneration with brain iron 
accumulation (Morgan, Westaway et al. 2006). 
    In the associated rs34311866 locus, amongst the tagged genes 
TMEM175, GAK and DGKQ, -synuclein was downregulated in GAK KD cell lines. 
G-protein coupled receptor-signaling pathway, inflammatory response and 
Cytokine-cytokine receptor interaction pathways were enriched in GAK KD 
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samples. GAK plays a role in the vesicle-mediated signaling pathway and 
clathrin-mediated signaling pathway. Published studies reveal that GAK modifies 
α-synuclein expression levels and toxicity in Parkinson’s disease (Dumitriu, 
Pacheco et al. 2011). According to the Ensembl genome browser 
(https://www.ensembl.org/index.html), TMEM175 and GAK are encoded on the 
two different strands of the DNA in a head-to-head orientation containing only 
one promoter region between them. Moreover, deficiency of TMEM175 increases 
α-synuclein aggregation by impairing lysosomal and mitochondrial function 
(Jinn, Drolet et al. 2017).  
   In GCH1 KD cell lines, α-synuclein was downregulated and G-
protein coupled receptor signaling pathway, cell surface receptor signaling 
pathway and chemokine-mediated signaling pathways were enriched. Published 
studies have reported GCH1 variants segregating with both dopa-responsive 
dystonia and Parkinson’s disease (Lewthwaite, Lambert et al. 2015). GCH1 
encodes the rate-limiting enzyme for tetrahydrobiopterin (BH4) biosynthesis, an 
essential cofactor of tyrosine hydroxylase (TH) activity and dopamine 
production in nigrostriatal cells (Cai, Alp et al. 2002).  
  α-synuclein mRNA levels were upregulated in COASY and ITGA8 
knockdown samples with respect to controls. Signaling pathways, microtubule-
based movement and activation of protein kinase activity were over-represented 
in COASY KD cell lines. A previous published report shows that a mutation in 
COASY causes neurodegeneration with brain iron accumulation (Annesi, 
Gagliardi et al. 2016). The protein encoded by ITGA8 is a membrane protein that 
mediates cell-cell interactions and regulates neurite outgrowth of sensory and 
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motor neurons (Farias, Lu et al. 2005). It is involved in integrin-mediated 
signaling pathways and apoptotic pathways.  
  The associated SNP rs12497850 is among the 17 new loci identified in the 
latest meta-analysis of PD GWAS (Chang, Nalls et al. 2017). The genes such as 
DALRD3, ARIH2, IMPDH2, P4HTM, PRKAR2A, QARS, QRICH1, USP19 and WDR6 
tagging this associated region (rs12497850) were knockdown. Amongst these 
knockdown genes -synuclein was upregulated in P4HTM KD cell lines. The 
protein encoded by P4HTM plays a role in catalyzing the post-translational 
formation of 4-hydroxyproline in hypoxia-inducible factor (HIF) alpha proteins. 
It contributes to the hydroxylation of proteasomal degradation by targeting HIF 
von Hippel-Lindau ubiquitination complex (Koivunen, Tiainen et al. 2007). The 
inflammatory response, G-protein coupled receptor signaling pathway and 
Calcium signaling pathway were over-represented in the differentially expressed 
genes of P4HTM KD samples compared to controls. Henceforth, we detected that 
on silencing parkinsonism causal genes (PARK7, VPS35 and PLA2G6) and 
targeted genes such as GAK, ITGA8, GCH1 and P4HTM, biological processes such 
as inflammatory response, G-protein coupled receptor signaling pathway and 
Cytokine-cytokine receptor interaction were over-represented. 
 Both rare and common variants in multiple genes contribute to PD 
pathogenesis. Rare coding variants affect the function of the gene and are also 
involved in the genetic aetiology of PD. Hence, we investigated the genetic 
burden of rare variants in the genes tagging the PD risk loci using resequencing 
data from IPDGC. Gene-based association tests show a significant association of 
LRRK2 and GAK to PD. These promising candidate genes such as BAG3, GAK, 
GCH1, ITGA8, COASY and P4HTM from the transcriptomic analysis will be 
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validated by functional assays such as Parkin translocation assay, an assay for α-
synuclein aggregation, secretion and toxicity and by investigating mitochondrial 
function using Seahorse. 
 
 
 
Table 19. Over-represented Biological processes and pathways in differentially regulated 
genes of knockdown samples. 
 
Loci KD_genes Biological Process Pathways 
TMEM175 GAK positive regulation of cell-substrate adhesion ; extracellular 
matrix organization ; response to lipopolysaccharide ; cellular 
response to mechanical stimulus ; immune response ; 
inflammatory response ; chondrocyte differentiation ; G-protein 
coupled receptor signaling pathway ; positive regulation of 
angiogenesis  
Malaria ; Cytokine-cytokine receptor 
interaction 
TMEM175 TMEM175 neuropeptide signaling pathway ; antibacterial humoral 
response ; defense response to Gram-negative bacterium 
 
PARK16 NUCKS1 cell surface receptor signaling pathway ; digestion ; response to 
lipopolysaccharide 
Neuroactive ligand-receptor interaction 
BAG3 BAG3 cell adhesion ; extracellular matrix organization ; cilium 
movement ; immune response ; positive regulation of cell-
substrate adhesion ; cell-matrix adhesion ; cell adhesion 
mediated by integrin ; chemical synaptic transmission ; cell-
substrate adhesion ; heterotypic cell-cell adhesion ; epidermis 
development ; integrin-mediated signaling pathway 
ECM-receptor interaction ; Hypertrophic 
cardiomyopathy (HCM) ; Dilated 
cardiomyopathy ; Arrhythmogenic right 
ventricular cardiomyopathy (ARVC) ; 
Focal adhesion 
BAG3 INPP5F cell adhesion ; chemical synaptic transmission ; extracellular 
matrix organization ; keratan sulfate biosynthetic process ; 
positive regulation of transforming growth factor beta receptor 
signaling pathway ; response to wounding ; regulation of ion 
transmembrane transport ; startle response ; collagen fibril 
organization ; sensory perception of pain 
ECM-receptor interaction 
BAG3 MCMBP immune response Neuroactive ligand-receptor interaction 
BAG3 RGS10 angiogenesis ; extracellular matrix organization ; positive 
regulation of angiogenesis ; endocrine pancreas development ; 
positive regulation of ERK1 and ERK2 cascade ; inflammatory 
response ; signal transduction ; chemical synaptic transmission 
; positive regulation of Notch signaling pathway ; cell adhesion ; 
Notch receptor processing ; positive regulation of collagen 
biosynthetic process ; negative regulation of apoptotic process ; 
peripheral nervous system development ; positive regulation of 
cell proliferation ; positive regulation of transforming growth 
factor beta receptor signaling pathway ; positive regulation of 
fibroblast proliferation 
Cytokine-cytokine receptor interaction ; 
Neuroactive ligand-receptor interaction 
BAG3 SEC23IP striated muscle contraction ; cell surface receptor signaling 
pathway ; G-protein coupled receptor signaling pathway ; G-
protein coupled receptor signaling pathway, coupled to cyclic 
nucleotide second messenger ; sarcomere organization ; 
cytokine-mediated signaling pathway ;  
 
BAG3 TIAL1 response to mechanical stimulus ; extracellular matrix 
organization ; response to estradiol ; cell surface receptor 
signaling pathway 
Neuroactive ligand-receptor interaction 
rs12497850 
 
DALRD3  Neuroactive ligand-receptor interaction 
rs12497850 
 
IMPDH2  Systemic lupus erythematosus 
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rs12497850 
 
P4HTM cholesterol biosynthetic process ; cell adhesion ; cell surface 
receptor signaling pathway ; G-protein coupled receptor 
signaling pathway ; potassium ion transmembrane transport ; 
regulation of ion transmembrane transport ; ion 
transmembrane transport ; positive regulation of angiogenesis ; 
single organismal cell-cell adhesion ; regulation of membrane 
potential ; potassium ion transport ; positive regulation of 
synapse assembly ; regulation of cardiac conduction ; 
inflammatory response ; potassium ion import ; negative 
regulation of blood pressure ; extracellular matrix organization 
; sensory perception of taste ; skeletal system development ; G-
protein coupled receptor signaling pathway, coupled to cyclic 
nucleotide second messenger ; sodium ion transmembrane 
transport ; nitric oxide mediated signal transduction ; 
regulation of heart contraction ; arachidonic acid metabolic 
process ; collagen catabolic process ; cholesterol homeostasis ; 
adherens junction organization ; cytokine-mediated signaling 
pathway ; bile acid and bile salt transport ; axonogenesis ; 
negative regulation of insulin secretion ; calcium ion-regulated 
exocytosis of neurotransmitter ; immune response ; 
keratinization ; linoleic acid metabolic process ; cholesterol 
transport ; cell development ; positive regulation of peptidyl-
tyrosine phosphorylation ; oxidation-reduction process ; 
cellular response to follicle-stimulating hormone stimulus 
Neuroactive ligand-receptor interaction ; 
Calcium signaling pathway ; Protein 
digestion and absorption ; Cytokine-
cytokine receptor interaction ; Steroid 
biosynthesis ; Terpenoid backbone 
biosynthesis ; Hematopoietic cell lineage ; 
Glycosphingolipid biosynthesis - lacto and 
neolacto series ; Taste transduction 
rs12497850 
 
PRKAR2A extracellular matrix organization ; G-protein coupled receptor 
signaling pathway ; negative regulation of adenylate cyclase 
activity ; neuropeptide signaling pathway ; cell adhesion ; 
phospholipase C-activating G-protein coupled receptor 
signaling pathway ; regulation of vasoconstriction ; 
mesodermal cell differentiation ; angiogenesis ; extracellular 
matrix disassembly ; cell surface receptor signaling pathway 
Neuroactive ligand-receptor interaction ; 
Cytokine-cytokine receptor interaction ; 
ECM-receptor interaction 
rs12497850 
 
QARS cell adhesion ; extracellular matrix organization ; homophilic 
cell adhesion via plasma membrane adhesion molecules ; 
wound healing ; negative regulation of angiogenesis ; positive 
regulation of cell proliferation ; G-protein coupled receptor 
signaling pathway, coupled to cyclic nucleotide second 
messenger ; response to lipopolysaccharide ; keratan sulfate 
biosynthetic process ; cellular response to retinoic acid ; 
synapse assembly ; nervous system development ; lung 
development ; neural crest cell migration ; angiogenesis ; 
response to hypoxia ; chemokine-mediated signaling pathway ; 
inflammatory response ; cell surface receptor signaling 
pathway ; positive regulation of smooth muscle cell 
proliferation ; positive regulation of cell-substrate adhesion ; 
response to corticosterone ; signal transduction ; response to 
mechanical stimulus ; negative regulation of endothelial cell 
migration ; immune response ; heart development ; cell-cell 
signaling ; positive regulation of ERK1 and ERK2 cascade ; 
positive regulation of collagen biosynthetic process ; 
vasodilation ; skeletal system development ; response to 
activity ; positive regulation of cell migration ; cation transport ; 
response to wounding ; cellular response to interleukin-1 ; 
negative regulation of endothelial cell apoptotic process ; 
keratinocyte differentiation ; endothelial cell differentiation ; 
induction of positive chemotaxis ; regulation of postsynaptic 
membrane potential ; cell-matrix adhesion ; regulation of 
immune response 
Neuroactive ligand-receptor interaction ; 
ECM-receptor interaction ; Cell adhesion 
molecules (CAMs) ; Axon guidance ; 
Arrhythmogenic right ventricular 
cardiomyopathy (ARVC) ; Dilated 
cardiomyopathy ; Hypertrophic 
cardiomyopathy (HCM) ; Malaria ; 
Calcium signaling pathway ; Focal 
adhesion 
rs12497850 
 
QRICH1 cytokine-mediated signaling pathway ; chemical synaptic 
transmission 
 
rs12497850 
 
WDR6 striated muscle contraction  
rs14235 KAT8 cytokine-mediated signaling pathway ; skeletal muscle 
contraction 
 
rs14235 STX4 MAPK cascade  ;  chemical synaptic transmission  ;  regulation 
of phosphatidylinositol 3-kinase signaling  ;  positive regulation 
of Ras protein signal transduction  ;  positive regulation of ERK1 
and ERK2 cascade  ;  
Cytokine-cytokine receptor interaction 
rs14235 VKORC1 vasodilation Neuroactive ligand-receptor interaction 
rs14235 ZNF668 cell adhesion  ;  extracellular matrix organization  
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SREBF1 SREBF1 G-protein coupled receptor signaling pathway,extracellular 
matrix organization,blood vessel remodeling 
 
ATP13A2 ATP13A2 chemical synaptic transmission ; cell surface receptor signaling 
pathway ; G-protein coupled receptor signaling pathway 
- 
BST1 BST1 extracellular matrix organization ; response to growth factor ; 
G-protein coupled receptor signaling pathway ; platelet 
degranulation ; inflammatory response ; gastrulation ; cytokine-
mediated signaling pathway ; response to estradiol ; response 
to cAMP ; ERK1 and ERK2 cascade 
Neuroactive ligand-receptor interaction ; 
Cytokine-cytokine receptor interaction ; 
Hematopoietic cell lineage 
COASY COASY mitotic nuclear division ; sister chromatid cohesion ; cell 
division ; DNA replication ; regulation of transcription involved 
in G1/S transition of mitotic cell cycle ; chromosome 
segregation ; G1/S transition of mitotic cell cycle ; extracellular 
matrix organization ; cell adhesion ; mitotic sister chromatid 
segregation ; extracellular matrix disassembly ; DNA replication 
initiation ; metaphase plate congression ; mitotic cytokinesis ; 
potassium ion transport ; CENP-A containing nucleosome 
assembly ; cytokine-mediated signaling pathway ; mitotic 
spindle organization ; cell proliferation ; regulation of cyclin-
dependent protein serine/threonine kinase activity ; mitotic 
metaphase plate congression ; glycosaminoglycan metabolic 
process ; retinoid metabolic process ; microtubule-based 
movement ; spindle organization ; positive regulation of 
cytokinesis ; activation of protein kinase activity ; retina 
homeostasis ; chromosome organization ; immune response ; 
cytokinesis ; spermatogenesis ; regulation of mitotic 
metaphase/anaphase transition ; DNA duplex unwinding ; 
strand displacement ; collagen fibril organization 
Cell cycle ; ECM-receptor interaction ; 
Progesterone-mediated oocyte 
maturation ; Oocyte meiosis ; 
Hypertrophic cardiomyopathy (HCM) ; 
Dilated cardiomyopathy 
FDFT1 FDFT1 immune response - 
rs11158026 GCH1 immune response ; G-protein coupled receptor signaling 
pathway ; cell surface receptor signaling pathway ; platelet 
degranulation ; defense response to Gram-negative bacterium ; 
chemokine-mediated signaling pathway ; response to pain 
Cytokine-cytokine receptor interaction ; 
Intestinal immune network for IgA 
production 
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Project 4: Genetic interaction of LRRK2 and 
PARK16 locus in Parkinson’s disease using next 
generation sequencing data. 
 
4.1 Introduction 
Genome-Wide Association Studies (GWAS) have provided unequivocal evidence 
of a genetic contribution of common variability to Parkinson’s disease (PD) 
(Chang, Nalls et al. 2017). Although these studies have been successful in the 
identification of 41 risk loci for sporadic PD and supported the concept that 
sporadic and familial PD share multiple pathogenic pathways, the underlying 
mechanisms for the majority of them remain elusive. The main reason being that 
they only identify haplotypes of common variants, which in most cases are not 
functionally relevant but rather exist in linkage disequilibrium with the variants 
conferring the risk effect, which can only be identified by resequencing these loci 
in a large number of individuals. In our study, we used available NGS data and 
tried to understand the genetic mechanisms underlying the risk for PD in one of 
the first GWAS loci identified for this disorder, i.e. PARK16. This locus was 
identified for the first time in a Japanese GWAS (Satake, Nakabayashi et al. 2009) 
and was confirmed in European populations (Simon-Sanchez, Schulte et al. 
2009). It spans 170kb region in chromosome 1 and contains five protein-coding 
genes, namely SLC45A3, NUCKS1, RAB29, SLC41A1 and PM20D1.  
 Although several sequencing approaches aiming to understand the 
genetic variant responsible for PD in this locus, coding variants have been 
identified in RAB29 (p. K157R) and SLC41A1 (p. A350V) in a British PD cohort, 
but failed to replicate in a larger cohort (Tucci, Nalls et al. 2010). Lin et al. 
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reported that variant p. R244H in SLC41A1 causes loss of Mg2+ efflux function 
(Evangelou, Maraganore et al.). These previous reports suggest that the 
identified variants are very rare and may or may not be a disease causal one, as 
they aren’t replicated yet.  
 David MacLeod et al. performed human genetic, transcriptomic and 
cellular analysis and described that interaction between LRRK2 and PARK16 
locus is associated with PD risk (MacLeod, Rhinn et al. 2013). However, amongst 
the five genes of PARK16, only RAB29 overexpression suppressed the neurite 
length phenotype induced by LRRK2 (MacLeod, Rhinn et al. 2013) pointing to 
this gene as the most interesting candidate within this locus. Defects in RAB29 
and LRRK2 due to PD led to endolysosomal and Golgi apparatus defects and 
deficiency of the retromer complex component VPS35 (MacLeod, Rhinn et al. 
2013).   
 In this study, we interrogated next-generation sequencing (NGS) data of 
unrelated cases and controls to investigate the interaction between LRRK2 and 
PARK16 locus. Moreover, we presented the analysis of resequencing data in 
LRRK2 and PARK16 in a large series of PD cases and controls and tried to 
replicate the molecular interaction between these two loci. 
4.2 Subjects 
 
4.2.1 Discovery phase:  
 
We performed a two-stage study. Firstly, we did a discovery analysis in which 
the Whole Exome Sequencing (WES) data was interrogated. To investigate for a 
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genetic interaction between LRRK2 and PARK16 we used our large repository of 
WES data of Caucasian population, which consists of 1,450 PD cases and 535 
controls from the International Parkinson’s Disease Consortium (IPDGC) and 
1,732 controls from the Rotterdam Study Exome Sequencing Database.  
 
4.2.2 Replication:  
In order to replicate the results obtained, we used NGS data generated for the 11 
PD risk loci such as MAPT, SNCA, HLA-DRB5, BST1, GAK, LRRK2, ACMSD, STK39, 
MCCC1/LAMP3, SYT11, and CCDC62/HIP1R as per the meta-analysis of 2011 
(International Parkinson Disease Genomics, Nalls et al. 2011). Data from 3,060 
PD cases and 1,454 controls from Caucasian series were available in this dataset 
including LRRK2 and PARK16 locus (International Parkinson Disease Genomics, 
Nalls et al. 2011). 
 
4.3 Methodology: 
 
Quality control of both the datasets are discussed in detail in the previous 
chapters. Genotype and variant quality control was performed for both datasets 
using KGGSeq (Cingolani, Platts et al. 2012) and VCFtools (Danecek, Auton et al. 
2011, Cingolani, Platts et al. 2012). Individual quality control of the data consists 
of identification of gender inconsistencies, heterozygosity outliers, duplicate 
samples, individuals of divergent ancestry and missing genotype. All these 
individuals were removed from both datasets.  
An epistatic interaction between LRRK2 SNPs and PARK16 locus SNPs 
along with marginal association was estimated using Bayesian Epistasis 
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Association Mapping (BEAM) tool (Zhang 2012), which is particularly useful for 
case-control studies. It uses Bayesian partitioning model and computes the 
posterior probability that each marker set is associated with the disease 
employing Markov chain Monte Carlo method (Zhang 2012). Also, the B-statistic 
of BEAM is more potent than the χ2 statistic of exhaustive search. BEAM takes 
into account SNP linkage disequilibrium (LD), so the identified interactions are 
not due to LD effects but are associated with the disease. The interacting SNPs 
are jointly affecting the disease, and their joint contribution to disease risk is 
stronger than their marginal contribution individually (Zhang 2012). 
 
4.4 Results 
 
4.4.1 Discovery phase:  
After performing epistatic analysis of LRRK2 and PARK16 SNPs, it was observed 
that there is a significant interaction between LRRK2 intronic variant 
rs138343113 and SLC41A1 intronic variant rs5780304. The joint posterior 
probability for marginal association (0.84) and interaction association (0.16) 
together for rs5780304 is 1.0 and for rs138343113 is 0.165 (table20). 
4.4.2 Replication:  
In order to replicate the findings, epistatic analysis of resequenced PD loci 
dataset was performed using Bayesian epistasis association mapping approach. 
It was observed that the SNP pairs from the discovery set did not replicate. 
However, both discovery and replication datasets are different, so we expect that 
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different SNPs pairs of LRRK2 and SLC41A1 might be involved in the interaction. 
Therefore, after inspecting the SNP pairs of SLC41A1 and LRRK2, it was observed 
that SLC41A1 intronic variant rs5780303 interacts with LRRK2 intronic variant 
rs528054842. Posterior probability for marginal association and interaction 
association together for rs5780303 and all associated SNPs within 1Mb region is 
2.100 and for rs528054842 along with all associated SNPs within 1Mb region of 
chr12 is 3.110. SNPs such as rs721711 and rs7307276 in LRRK2 and rs5780304 
variant in SLC41A1 has interaction association probability greater than 50% 
(table21).  
 SLC41A1 SNPs such as rs5780304 (discovery set) and rs5780303 
(replication set) are in LD (r2 = 0.98) as well as LRRK2 SNPs such as 
rs138343113 (discovery set) and rs721711, rs7307276 (replication set) are also 
in LD (r2 = 0.61) [9]. Hence, we observed same effect in both discovery and 
replication dataset. 
 
 
Table 20: Epistasis results of discovery phase. 
Gene rsID CHR POS MARGINAL INTERACTION 
JOINT 
PROB 
SLC41A1 rs5780304 1 205766159 0.84 0.16 1 
LRRK2 rs138343113 12 40681142 0 0.155 0.155 
* CHR: Chromosome; POS: position; MARGINAL: Posterior probability of marginal association; 
INTERACTION: Posterior probability of interaction association; JOINTPROB: Joint posterior probability. 
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Table 21: Epistasis results of replication phase. 
Gene rsID CHR POS MARGINAL INTERACTION 
JOINT 
PROB 
SLC41A1 rs5780303 1 205765590 0.005 0.995 1 
LRRK2 rs528054842 12 40635005 0.22 0.78 1 
LRRK2 rs721711 12 40709328 0 1 1 
LRRK2 rs7307276 12 40715013 0 0.995 0.995 
SLC41A1 rs5780304 1 205766159 0 0.645 0.645 
* CHR: Chromosome; POS: position; MARGINAL: Posterior probability of marginal association; 
INTERACTION: Posterior probability of interaction association; JOINTPROB: Joint posterior probability. 
 
 
 
 
4.5  Discussion 
Previous studies draw our attention that variation in genes in PARK16 locus and 
LRRK2 interactively determine risk for PD (MacLeod, Rhinn et al. 2013). 
Furthermore, previous cellular studies implicate that LRRK2 and RAB29 (which 
is in PARK16 locus) work together and mutation in LRRK2 impairs lysosomal 
pathway. RAB29 is localized in Golgi and retromer complex is involved in protein 
sorting between lysosomes and Golgi. Therefore, any defects caused due to 
LRRK2 mutants could be due to impairment of retromer complex (MacLeod, 
Rhinn et al. 2013). Lisa Wang et al. reported that they did not identify an 
interaction between LRRK2 and PARK16 locus in a large multi-center series of PD 
cases and controls. Their analysis was limited to 5 SNPs from PARK16 locus and 
2 SNPs from LRRK2, which are shown to be associated with PD in the previous 
studies (Wang, Heckman et al.). However, NGS data has more coverage, so there 
is a possibility for other SNPs from LRRK2 and PARK16 locus to interact with 
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each other. We analyzed an interaction between all SNPs of LRRK2 and PARK16 
locus using WES data of unrelated cases and controls. Additionally, resequencing 
data of PD risk loci was used to replicate our findings. To estimate genetic 
interaction, we used Bayesian partitioning model approach, which gives the 
posterior probability for both interaction and marginal association. In our 
analysis, we did not find an interaction between RAB29 and LRRK2. In WES data 
(discovery dataset), an interaction between SLC41A1 rs5780304 and LRRK2 
rs138343113 was observed, which is not only marginally associated to PD but 
also has a joint contribution to PD risk. Though the interacting SNP pairs from 
WES data (discovery dataset) didn’t replicate in the resequencing data, there is 
still an interaction between SLC41A1 rs5780303 and LRRK2 rs52805484. 
SLC41A1 variants such as rs5780303 and rs5780304 interacting with LRRK2 
SNPs are in strong LD and are present in the intronic region. Cornelis 
Blauwendraat et al. identified an eQTL for an antisense CAGE cluster to SLC41A1. 
Moreover, they mentioned eQTL association of two PD GWAS associated 
variants, i.e. rs947211, (which is located 8.5 kb upstream of RAB29 and 5.6 kb 
downstream of SLC41A1) and rs823118 (4.2kb upstream of NUCKS1) with the 
expression of SLC41A1 antisense transcript (Blauwendraat, Francescatto et al. 
2016). SLC41A1 acts as magnesium transporter and might play a role in 
magnesium homeostasis. It has been reported that magnesium interacts with -
synuclein to inhibit -synuclein aggregation (Golts, Snyder et al. 2002). 
Moreover, an involvement of metal dyshomeostasis in neurodegeneration has 
been previously speculated (Myhre, Utkilen et al. 2013). Hence, SLC41A1 of 
PARK16 locus looks like an interesting candidate and may play a role in 
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developing a risk for PD. Moreover, functional study of this gene should be 
carried out to know the involvement of this gene in developing PD. 
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General Discussion 
 
Parkinson’s disease (PD) is a neurological disease that lacks therapies to modify 
the disease pathology. Medications can control the PD symptoms, but in an 
advanced stage of the disease, the medicines become less effective (Savitt, 
Dawson et al. 2006). The identification of causal rare genetic mutations 
facilitates the detection of deregulated biological processes in PD. Such findings 
are essential to improve our knowledge of PD pathogenesis. The main aim of this 
thesis was to identify genetic risk variants and pathogenic mutations 
contributing to PD pathogenesis.   
 The reduced cost of next-generation sequencing (NGS) has facilitated the 
family-based sequencing analysis to identify the causal genes for Mendelian 
disorders. In project 1 of this thesis, we sequenced and investigated the genomes 
(180 individuals) and exomes (20 individuals) from 126 families (discovery 
cohort). We identified pathogenic causal variants in already known 
parkinsonism causal genes such as LRRK2, DJ1, PARK2 and PLA2G6 in some 
families. A novel alternative homozygous mutation in TREM2 was identified in a 
Turkish patient with parkinsonism and dementia. Lines of evidence have shown 
that mutations in TREM2 not only cause Nasu-Hakola disease (Paloneva, 
Manninen et al. 2002) but were also identified in families with Frontotemporal 
dementia (FTD) (Guerreiro, Lohmann et al. 2013, Le Ber, De Septenville et al. 
2014). Moreover, TREM2 variants are also associated with Alzheimer’s disease 
(AD) risk (Guerreiro, Wojtas et al. 2013). In our study, we identified a 
hemizygous mutation in a novel gene SH3KBP1 in PD patients from two 
unrelated families. 
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On the basis of previous knowledge that SH3KBP1 plays a role in apoptosis 
(Narita, Nishimura et al. 2005) Bian et al. silenced SH3KBP1 expression in human 
dopaminergic SH-SY5Y cell lines using shRNA and observed that the cell death 
was decreased by 50% in comparison to controls (Bian, Yu et al. 2008).  In 
families with an autosomal recessive mode of inheritance, alternative 
homozygous and compound heterozygous mutations were identified in HTT, 
CCDC154, CXorf22, TMEM63C, MYO15A and ULK2. Heterozygous mutations in 
DYSF and APC2 were identified in multiple families with an autosomal dominant 
mode of inheritance. These 8 candidate genes were also identified in a large 
repository of sporadic PD WES data from Parkinson’s disease Genetics 
Sequencing Consortium (PDGSC) with a minor allele frequency (MAF) less than 
1% in public databases. 
 To test the association of rare variants/genes identified in the families to 
PD, we had a possibility of doing either burden test or variance-component test. 
In burden test, the phenotype is influenced by all the tested variants in the same 
direction (Auer and Lettre 2015).  To overcome this limitation, we performed 
SKAT-O test, which is a combination of burden test (all variants have the same 
direction of effect) and SKAT test (all variants have a distinct direction of effect). 
These rare variant association studies are sensitive to confounding factors (Lee, 
Emond et al. 2012). To deal with these confounding factors, we used 20 
multidimensional scaling components as covariates in the association analysis.  
By performing, gene-based SKAT-O tests using sporadic PD data, we observed 
that only rare variants in ULK2 are enriched to PD in both replication cohorts. 
Among these 8 candidates, HTT and ULK2 are highly promising as HTT is already 
linked to a neurological disorder and plays a role in vesicle-mediated transport, 
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apoptotic process and positive regulation of mitophagy (Schulte and Littleton 
2011). Furthermore, ULK2 is involved in autophagy and alteration of such 
autophagy-related proteins are observed in Lewy body disease (Jung, Seo et al. 
2011, Miki, Tanji et al. 2016). 
 PD is heterogeneous in terms of genetic, pathological and clinical point of 
view, so targeting biological pathways will be helpful to treat a group of PD 
patients. Genetic evidence shows that mitochondrial dysfunction may be one of 
the important disease pathways in a subgroup of PD patients (Reeve, Grady et al. 
2018).  In project 2, we identified the sub-group, i.e. the mitochondrial endo-
phenotype of PD using existing genomic data. The risk profiling of 8 GWAS 
associated SNPs showed that positive allelic scores were significantly present in 
more cases than in controls, while negative scores were present in more controls 
than in cases. The German PD cases were stratified as mito+ (allelic score > 0.35) 
and mito- (allelic score < -0.35) group on the basis of these allelic scores. Some 
patients from these two subgroups as well as PD patients with PARK2 and PINK1 
mutations will undergo clinical trials with coenzyme Q10 and vitamin K2. Rare 
variant association analysis showed that only GBA is associated with PD in both 
datasets. The other genes, which showed association signals in WES data were 
not replicated in NeuroX, as the age of onset and the laboratory techniques 
applied to both the datasets are different.   
 Genome-wide association studies (GWAS) have identified many common 
genetic variants associated to PD (Pankratz, Wilk et al. 2009, Satake, 
Nakabayashi et al. 2009, Simon-Sanchez, Schulte et al. 2009, Nalls, Pankratz et al. 
2014, Chang, Nalls et al. 2017). In project 3, the genes spanning the PD GWAS 
associated regions were investigated to identify the actual gene contributing to 
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PD risk. The genes under the associated PD loci were silenced by shRNA, and the 
gene expression was quantified using mRNA sequencing. -synuclein, which is 
pathologically and genetically linked to PD, was differentially regulated in genes 
such as BAG3, GAK, GCH1, ITGA8, COASY and P4HTM. Functional validation of 
these genes is needed to detect their role in PD pathogenesis. 
 Despite the identified risk loci for PD through GWAS, a single SNP 
association explains the limited heritability of the disease, so multi-SNP 
interactions, i.e. epistatic interactions are a hope to discover more significant 
associations. The published report has shown that an interaction between 
Mendelian PD gene LRRK2 and PARK16 locus is associated with PD risk 
(MacLeod, Rhinn et al. 2013). In project 4, we identified an epistatic interaction 
between LRRK2 and SLC41A1 of PARK16 locus using Bayesian partitioning model 
approach. An eQTL has already been identified for an antisense CAGE cluster to 
SLC41A1 (Blauwendraat, Francescatto et al. 2016). SLC41A1 plays a role in 
magnesium homeostasis and involvement of metal dyshomeostasis in 
neurodegeneration makes the gene more interesting for functional validation 
(Golts, Snyder et al. 2002, Myhre, Utkilen et al. 2013). 
 In this thesis, we identified pathogenic variants in some novel genes 
causing PD in families. Gene-based association tests using sporadic PD data also 
shows that rare variants in some novel genes are highly enriched. In the future, 
functional validation of these candidates has to be done using cellular or animal 
model to determine their role in PD pathogenesis. 
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